Nothing Special   »   [go: up one dir, main page]

EP2812443B1 - Cd47-antikörper und verfahren zur verwendung davon - Google Patents

Cd47-antikörper und verfahren zur verwendung davon Download PDF

Info

Publication number
EP2812443B1
EP2812443B1 EP13746964.9A EP13746964A EP2812443B1 EP 2812443 B1 EP2812443 B1 EP 2812443B1 EP 13746964 A EP13746964 A EP 13746964A EP 2812443 B1 EP2812443 B1 EP 2812443B1
Authority
EP
European Patent Office
Prior art keywords
seq
set forth
sequence set
antibody
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP13746964.9A
Other languages
English (en)
French (fr)
Other versions
EP2812443A4 (de
EP2812443A1 (de
Inventor
Brendan ECKELMAN
John Timmer
Amir RAZAI
Quinn Deveraux
Kyle Jones
Peter L. NGUY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inhibrx Inc
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48947976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2812443(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PL13746964T priority Critical patent/PL2812443T3/pl
Priority to MEP-2019-232A priority patent/ME03512B/de
Priority to SI201331564T priority patent/SI2812443T1/sl
Priority to RSP20191071 priority patent/RS59159B1/sr
Priority to EP19173042.3A priority patent/EP3578569A1/de
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of EP2812443A1 publication Critical patent/EP2812443A1/de
Publication of EP2812443A4 publication Critical patent/EP2812443A4/de
Publication of EP2812443B1 publication Critical patent/EP2812443B1/de
Application granted granted Critical
Priority to HRP20191500 priority patent/HRP20191500T1/hr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Definitions

  • This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of hemagglutination of human red blood cells, to methods of generating these antibodies, and to these monoclonal antibodies for use as therapeutics.
  • CD47 also known as integrin-associated protein (I ⁇ P), ovarian cancer antigen OA3, Rh-related antigen and MER6, is a multi-spanning transmembrane receptor belonging to the immunoglobulin superfamily. CD47 expression and/or activity have been implicated in a number of diseases and disorders. Accordingly, there exists a need for therapies that target CD47.
  • I ⁇ P integrin-associated protein
  • OA3 ovarian cancer antigen
  • Rh-related antigen MER6
  • CD47 expression and/or activity have been implicated in a number of diseases and disorders. Accordingly, there exists a need for therapies that target CD47.
  • Babic et al. uses an anti-CD47 antibody (mIAP301) to investigate whether CD47 played a role in the aggregation of SHPS-1-expressing Ba/F3 cells ( The Journal of Immunology, 2000, 164: 3652-3658 ).
  • Majeti et al. discloses several anti-CD47 antibodies ( Cell, 2009, 138:286-299 ).
  • Chao et al. investigates the role of an anti-CD47 antibody in treating human acute lymphoblastic leukemia ( Cancer Res. 2011, 71:1374-1384 ).
  • the present invention provides an isolated monoclonal antibody or immunologically active fragment thereof that binds to human CD47, wherein the antibody or immunologically active fragment thereof binds to a discontinuous epitope on CD47, wherein the discontinuous epitope comprises amino acids residues Y37, K39, K41, K43, G44, R45, D46, D51, H90, N93, E97, T99, E104, and E106 of CD47 when numbered in accordance with SEQ ID NO: 147, and wherein the antibody or immunologically active fragment thereof prevents CD47 from interacting with signal-regulatory-protein ⁇ (SIRP ⁇ ) and does not cause a significant level of agglutination of cells after administration.
  • SIRP ⁇ signal-regulatory-protein ⁇
  • the antibody or immunologically active fragment thereof is chimeric or humanized.
  • the antibody or immunologically active fragment thereof promotes macrophage-mediated phagocytosis of a CD47-expressing cell.
  • the antibody or immunologically active fragment thereof is an IgG isotype selected from the group consisting of IgG 1 isotype, IgG2 isotype, IgG3 isotype, and IgG4 isotype.
  • the antibody or immunologically active fragment thereof is an IgG isotype selected from IgG4P and IgG4PE.
  • the antibody or immunologically active fragment thereof comprises:
  • the antibody or immunologically active fragment thereof comprises:
  • the present invention further provides a pharmaceutical composition comprising the antibody or immunologically active fragment thereof of the invention and a carrier.
  • the present invention further provides an antibody or an immunologically active fragment thereof of the invention for use in a method of alleviating a symptom of a cancer or other neoplastic condition in a subject.
  • the subject is a human.
  • the method further comprises administering chemotherapy.
  • the method further comprises administering radiotherapy.
  • the present invention provides monoclonal antibodies that recognize and bind to CD47, particularly human CD47.
  • the antibodies of the invention are capable of modulating, e.g ., blocking, inhibiting, reducing, antagonizing, neutralizing or otherwise interfering with CD47 expression, activity and/or signaling, and these antibodies do not cause a significant level of hemagglutination of human red blood cells, also referred to herein as erythrocytes.
  • the ability of the antibodies of the present invention to bind CD47 on the cell surface and not cause a cellular clumping phenomenon is not limited to red blood cells.
  • the antibodies of the present invention uniquely bind CD47 in a manner that does not promote clumping of CD47 positive cells.
  • the antibodies of the invention and derivatives thereof are capable of modulating, e.g ., blocking, inhibiting, reducing, antagonizing, neutralizing or otherwise interfering with the interaction between CD47 and SIRP ⁇ (signal-regulatory-protein ⁇ ), and these antibodies do not cause a significant level of hemagglutination of human red blood cells.
  • the antibodies provided herein are referred to collectively as "CD47 antibodies.”
  • the CD47 antibodies of the invention are a significant improvement over existing CD47 antibodies that cause hemagglutination of human red blood cells ( See , e.g ., Kikuchi Y, Uno S, Yoshimura Y et al.
  • the CD47 antibodies of the invention are a significant improvement over the existing CD47 antibodies B6II12, BRIC126, and CC2C6, each of which block SIRP ⁇ , but cause hemagglutination of RBCs, as described in detail below.
  • the full IgG CD47 antibodies of the present invention e.g ., 2A1 and its humanized derivatives including those provided in Table 1
  • the CD47 antibodies of the invention do not hemagglutinate red blood cells (RBCs). Described herein are the first CD47 antibodies in a full IgG format that block SIRP ⁇ and do not cause a significant level of agglutination.
  • the CD47 antibodies of the invention exhibit numerous desirable characteristics, such as, by way of non-limiting example, potent blocking of the interaction between CD47 and its ligand SIRP ⁇ , without causing a significant level of hemagglutination of erythrocytes, as well as potent anti-tumor activity.
  • the CD47 antibodies of the invention block at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 95%, or at least 99% of the interaction between CD47 and SIRP ⁇ as compared to the level of interaction between CD47 and SIRP ⁇ in the absence of the CD47 antibody described herein.
  • the CD47 antibodies of the invention do not cause a significant level of agglutination of cells, e.g., the CD47 antibodies of the invention do not cause a significant level of hemagglutination of red blood cells.
  • a significant level of agglutination of cells refers to the level of agglutination in the presence of existing CD47 antibodies.
  • the level of agglutination in the presence of the CD47 antibodies of the invention is reduced by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 99% compared to the level of agglutination in the presence existing CD47 antibodies.
  • the CD47 antibodies of the invention do not cause a significant level of agglutination if the level of agglutination in the presence of the CD47 antibodies of the invention is reduced by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 99% compared to the level of agglutination in the presence of existing CD47 antibodies.
  • the CD47 antibodies of the invention do not cause a significant level of agglutination if the level of agglutination in the presence of the CD47 antibodies of the invention is reduced by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 99% compared to the level of agglutination in the presence of CD47 antibody, 1B4, which comprises a variable heavy and variable light chain sequence provided in SEQ ID NO: 80 and SEQ ID NO: 81, respectively.
  • the CD47 antibodies of the invention do not cause a significant level of agglutination of cells at an antibody concentration of between 10 pM and 10 ⁇ M, e.g., at an antibody concentration of 50 pM, 100 pM, 1 nM, 10 nM, 50 nM, 100 nM, 1 ⁇ M, or 5 ⁇ M.
  • the antibodies of the present invention are also significantly more potent in tumor models compared to antibodies known in the art.
  • the ability of macrophages to phagocytose tumor cells in the presence of CD47 antibodies of the invention is increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 99% compared to the ability of macrophages to phagocytose tumor cells in the presence of existing CD47 antibodies.
  • the level of agglutination e.g ., the level of hemagglutination of RBCs.
  • the level of hemagglutination is ascertained by measuring the area of an RBC dot after performing a hemagglutination assay in the presence of the CD47 antibodies of the invention, as described in the Examples below. In some cases, the area of the RBC dot in the presence of the CD47 antibody of the invention is compared to the area of the RBC dot in the absence of a CD47 antibody, i.e ., in the presence of zero hemagglutination.
  • hemagglutination is quantified relative to a baseline control.
  • a larger RBC dot area corresponds to a higher level of hemagglutination.
  • densitometry of the RBC dot may also be utilized to quantitate hemagglutination.
  • the CD47 antibodies described herein are useful in treating, delaying the progression of, preventing relapse of or alleviating a symptom of a cancer or other neoplastic condition.
  • the CD47 antibodies described herein are useful in treating hematological malignancies and/or tumors, e.g., hematological malignancies and/or tumors.
  • the CD47 antibodies described herein are useful in treating CD47+ tumors.
  • the CD47 antibodies described herein are useful in treating non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), multiple myeloma (MM), breast cancer, ovarian cancer, head and neck cancer, bladder cancer, melanoma, colorectal cancer, pancreatic cancer, lung cancer, leiomyoma, leiomyosarcoma, glioma, glioblastoma, and so on.
  • NHL non-Hodgkin's lymphoma
  • ALL acute lymphocytic leukemia
  • AML acute myeloid leukemia
  • CLL chronic lymphocytic leukemia
  • CML chronic myelogenous leukemia
  • MM multiple myeloma
  • breast cancer ovarian cancer
  • head and neck cancer bladder cancer
  • melanoma
  • Solid tumors include, e.g ., breast tumors, ovarian tumors, lung tumors, pancreatic tumors, prostate tumors, melanoma tumors, colorectal tumors, lung tumors, head and neck tumors, bladder tumors, esophageal tumors, liver tumors, and kidney tumors.
  • hematological cancer refers to a cancer of the blood, and includes leukemia, lymphoma and myeloma among others.
  • Leukemia refers to a cancer of the blood in which too many white blood cells that are ineffective in fighting infection are made, thus crowding out the other parts that make up the blood, such as platelets and red blood cells. It is understood that cases of leukemia are classified as acute or chronic.
  • leukemia include, by way of non-limiting example, acute lymphocytic leukemia (ALL); acute myeloid leukemia (AML); chronic lymphocytic leukemia (CLL); chronic myelogenous leukemia (CML); Myeloproliferative disorder/neoplasm (MPDS); and myelodysplasia syndrome.
  • ALL acute lymphocytic leukemia
  • AML acute myeloid leukemia
  • CLL chronic lymphocytic leukemia
  • CML chronic myelogenous leukemia
  • MPDS Myeloproliferative disorder/neoplasm
  • myelodysplasia syndrome myelodysplasia syndrome.
  • Lymphoma may refer to a Hodgkin's lymphoma, both indolent and aggressive non-Hodgkin's lymphoma, Burkitt's lymphoma, and follicular lymphoma (small cell and large cell), among others.
  • Exemplary monoclonal antibodies of the invention include, for example, the antibodies described herein.
  • Exemplary antibodies include antibodies having a variable heavy chain selected from SEQ ID NOs: 5-30 and a variable light chain selected from SEQ ID NOs: 31-47.
  • the antibodies also include antibodies having a variable heavy chain that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the sequence set forth in at least one of SEQ ID NOs: 5-30 and a variable light chain that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the sequence set forth in at least one of SEQ ID NOs: 31-47.
  • the antibodies recognize and bind to human CD47 and do not cause a significant level of hemagglutination of human red blood cells.
  • CD47 antibodies include fully human monoclonal antibodies, as well as humanized monoclonal antibodies and chimeric antibodies. These antibodies show specificity for human CD47, and they have been shown to modulate, e.g ., block, inhibit, reduce, antagonize, neutralize or otherwise interfere with CD47 expression, activity and/or signaling without causing a significant level of hemagglutination of red blood cells.
  • the CD47 antibodies provided herein exhibit inhibitory activity, for example by inhibiting CD47 expression (e.g., inhibiting cell surface expression of CD47), activity, and/or signaling, or by interfering with the interaction between CD47 and SIRP ⁇ .
  • the antibodies provided herein completely or partially reduce or otherwise modulate CD47 expression or activity upon binding to, or otherwise interacting with, CD47, e.g., a human CD47.
  • the reduction or modulation of a biological function of CD47 is complete, significant, or partial upon interaction between the antibodies and the human CD47 polypeptide and/or peptide.
  • the antibodies are considered to completely inhibit CD47 expression or activity when the level of CD47 expression or activity in the presence of the antibody is decreased by at least 95%, e.g., by 96%, 97%, 98%, 99% or 100% as compared to the level of CD47 expression or activity in the absence of interaction, e.g ., binding, with the antibody described herein.
  • the CD47 antibodies are considered to significantly inhibit CD47 expression or activity when the level of CD47 expression or activity in the presence of the CD47 antibody is decreased by at least 50%, e.g ., 55%, 60%, 75%, 80%, 85% or 90% as compared to the level of CD47 expression or activity in the absence of binding with a CD47 antibody described herein.
  • the antibodies are considered to partially inhibit CD47 expression or activity when the level of CD47 expression or activity in the presence of the antibody is decreased by less than 95%, e.g., 10%, 20%, 25%, 30%, 40%, 50%, 60%, 75%, 80%, 85% or 90% as compared to the level of CD47 expression or activity in the absence of interaction, e.g ., binding, with an antibody described herein.
  • Antibodies of the invention also include monoclonal antibodies that specifically bind CD47, wherein the antibody does not cause a significant level of agglutination, e.g ., red blood cell hemagglutination ("RBC hemagglutination").
  • the antibodies of the present invention uniquely bind CD47 in a manner that does not promote clumping of CD47 positive cells; however, the ability of the antibodies of the present invention to bind CD47 on the cell surface and not cause a cellular clumping phenomenon is not limited to red blood cells.
  • compositions according to the invention can include an antibody of the invention and a carrier, These pharmaceutical compositions can be included in kits, such as, for example, diagnostic kits.
  • the invention provides monoclonal antibodies that bind to CD47 or an immunologically active fragment thereof, wherein the antibody does not cause a significant level of agglutination of cells after administration, e.g., the antibody docs not cause a significant level of hemagglutination of red blood cells after administration.
  • the antibody is chimeric, humanized, or fully human.
  • the antibodies bind to human CD47.
  • the antibody or immunologically active fragment thereof prevents CD47 from interacting with SIRP ⁇ .
  • the antibodies are considered to completely inhibit the interaction of CD47 and SIRP ⁇ when the level of CD47/SIRP ⁇ interaction in the presence of the antibody is decreased by at least 95%, e.g ., by 96%, 97%, 98%, 99% or 100% as compared to the level of CD47/SIRP ⁇ interaction in the absence of interaction with the antibody, e.g ., binding with the antibody.
  • the antibodies are considered to partially inhibit CD47/SIRP ⁇ interaction when the level of CD47/SIRP ⁇ interaction in the presence of the antibody is decreased by less than 95%, e.g ., 10%, 20%, 25%, 30%. 40%, 50%, 60%, 75%, 80%, 85% or 90% as compared to the level of CD47/SIRP ⁇ interaction in the absence of interaction with the antibody, e.g ., binding with the antibody.
  • the amount of antibody sufficient to treat or prevent cancer in the subject is, for example, an amount that is sufficient to reduce CD47 signaling ( See , e.g ., Yamauchi et al., 2013 Blood, Jan 4. [Epub ahead of print ]; Soto-Pantoja et al., 2013 Expert Opin Ther Targets, 17: 89-103 ; Irandoust et al., 2013 PLoS One, Epub Jan 8 ; Chao et al., 2012 Curr Opin Immunol, 24 :225-32 ; Theocharides et al., 2012 J Exp Med, 209(10): 1883-99 ; Csányi et al., 2012 Arterioscler Thromb Vasc Biol, 32: 2966-73 ; Maxhimer et al., 2009 Sci Transl Med, 1: 3ra7 ; Sarfati et al., 2008 Curr Drug Targets, 9: 842-850 ; Miyashita
  • the amount of antibody sufficient to treat or prevent cancer in the subject is an amount that is sufficient to reduce the phagocytic inhibitory signal in macrophages generated by CD47/SIRP ⁇ interaction in the CD47/SIRP ⁇ signaling axis, i.e., the antibody of the invention promotes macrophage-mediated phagocytosis of a CD47-expressing cell.
  • reduced refers to a decreased CD47 signaling in the presence of the antibody of the invention.
  • CD47 mediated signaling is decreased when the level of CD47 signaling in the presence of a CD47 antibody of the invention is greater than or equal to 5%, 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, 95%, 99%, or 100% lower than a control level of CD47 signaling (i.e ., the level of CD47 signaling in the absence of the antibody).
  • Level of CD47 signaling is measured using any of a variety of standard techniques, such as, by way of non-limiting example, measurement of down-stream gene activation, and/or luciferase reporter assays responsive to CD47 activation. Those skilled in the art will appreciate that the level of CD47 signaling can be measured using a variety of assays, including, for example, commercially available kits.
  • the antibody or immunologically active fragment thereof is an IgG isotype.
  • the constant region of the antibody is of human IgG1 isotype, having an amino acid sequence:
  • the human IgG1 constant region is modified at amino acid Asn297 (Boxed, Kabat Numbering) to prevent to glycosylation of the antibody, for example Asn297Ala (N297A).
  • the constant region of the antibody is modified at amino acid Leu235 (Kabat Numbering) to alter Fc receptor interactions, for example Leu235Glu (L235E) or Leu235Ala (L235A).
  • the constant region of the antibody is modified at amino acid Leu234 (Kabat Numbering) to alter Fc receptor interactions, e.g ., Leu234Ala (L234A).
  • the constant region of the antibody is altered at both amino acid 234 and 235, for example Leu234Ala and Leu235Ala (L234A/L235A) (EU index of Kabat et al 1991 Sequences of Proteins of Immunological Interest ) .
  • the constant region of the antibody is of human IgG2 isotype, having an amino acid sequence:
  • the human IgG2 constant region is modified at amino acid Asn297 (Boxed, Kabat Numbering) to prevent to glycosylation of the antibody, e.g ., Asn297Ala (N297A).
  • the constant region of the antibody is of human IgG3 isotype, having an amino acid sequence:
  • the human IgG3 constant region is modified at amino acid Asn297 (Boxed, Kabat Numbering) to prevent to glycosylation of the antibody, e.g ., Asn297Ala (N297A).
  • the human IgG3 constant region is modified at amino acid 435 to extend the half-life, e.g., Arg435His (R435H) (EU index of Kabat et al 1991 Sequences of Proteins of Immunological Interest ) .
  • the constant region of the antibody is of human IgG4 isotype, having an amino acid sequence:
  • the human IgG4 constant region is modified within the hinge region to prevent or reduce strand exchange, e.g ., Ser228Pro (S228P). In other embodiments, the human IgG4 constant region is modified at amino acid 235 to alter Fc receptor interactions, e.g ., Leu235Glu (L235E). In some embodiments, the human IgG4 constant region is modified within the hinge and at amino acid 235, e.g ., Ser228Pro and Leu235Glu (S228P/L235E).
  • the human IgG4 constant region is modified at amino acid Asn297 (Kabat Numbering) to prevent to glycosylation of the antibody, e.g ., Asn297Ala (N297A). (EU index of Kabat et al 1991 Sequences of Proteins of Immunological Interest ) .
  • the human IgG constant region is modified to enhance FcRn binding.
  • Fc mutations that enhance binding to FcRn are Met252Tyr, Ser254Thr, Thr256Glu (M252Y, S254T, T256E, respectively) (Kabat numbering, Dall'Acqua et al 2006, J. Biol Chem Vol 281(33) 23514-23524 ), or Met428Leu and Asn434Ser (M428L, N434S) ( Zalevsky et al 2010 Nature Biotech, Vol 28(2) 157-159 ). (EU index of Kabat et al 1991 Sequences of Proteins of Immunological Interest ) .
  • the human IgG constant region is modified to alter antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC), e.g ., the amino acid modifications described in Natsume et al., 2008 Cancer Res, 68(10): 3863-72 ; Idusogie et al., 2001 J Immunol, 166(4): 2571-5 ; Moore et al., 2010 mAbs, 2(2): 181-189 ; Lazar et al., 2006 PNAS, 103(11): 4005-4010 , Shields et al., 2001 JBC, 276(9): 6591-6604 ; Stavenhagen et al., 2007 Cancer Res, 67(18): 8882-8890 ; Stavenhagen et al., 2008 Advan. Enzyme Regul., 48: 152-164 ; Alegre et al, 1992 J Immunol, 148: 3461-3468 ; Reviewed
  • the human IgG constant region is modified to induce heterodimerization.
  • having an amino acid modification within the CH3 domain at Thr366, which when replaced with a more bulky amino acid, e.g ., Try (T366W) is able to preferentially pair with a second CH3 domain having amino acid modifications to less bulky amino acids at positions Thr366, Leu368, and Tyr407, e.g ., Ser, Ala and Val, respectively (T366S/L368A/Y407V).
  • Heterodimerization via CH3 modifications can be further stabilized by the introduction of a disulfide bond, for example by changing Ser354 to Cys (S354C) and Y349 to Cys (Y349C) on opposite CH3 domains (Reviewed in Carter, 2001 Journal of Immunological Methods, 248: 7-15 ).
  • the invention also provides pharmaceutical compositions that include one or more monoclonal antibodies that bind to CD47 or an immunologically active fragment thereof, wherein the antibody does not cause a significant level of hemagglutination of red blood cells after administration.
  • Hemagglutination is an example of a homotypic interaction, wherein two CD47 expressing cells are caused to aggregate or clump when treated with a bivalent CD47 binding entity.
  • the ability of the antibodies of the present invention to bind CD47 on the cell surface and not cause a cellular clumping phenomenon is not limited to red blood cells.
  • the antibodies of the present invention have been observed to uniquely bind CD47 in a manner that does not promote clumping of CD47 positive cell lines, e.g ., Daudi cells.
  • the antibody comprises a variable heavy (VH) chain region selected from the group consisting of SEQ ID NOs: 5-30.
  • the antibody optionally comprises a variable light (VL) chain region selected from the group consisting of SEQ ID NOs: 31-47.
  • the antibody comprises a VH chain region selected from the group consisting of SEQ ID NOs: 5-30 and a VL chain region selected from the group consisting of SEQ ID NOs: 31-47.
  • the antibodies of the invention also include antibodies having a variable heavy chain that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the sequence set forth in at least one of SEQ ID NOs: 5-30 and a variable light chain that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the sequence set forth in at least one of SEQ ID NOs: 31-47.
  • the antibody comprises a VII region provided in any one of SEQ ID NOs: 5, 7, 8, 11, 15-17, 20-22, and 27-30 paired with a VL region provided in any one of SEQ ID NOs: 31-39, 42, 43, 44, and 47.
  • the antibody comprises a VH region provided in any one of SEQ ID NOs: 5, 7, 8, 11, 12, 15-17, 20-22, and 27-30 paired with a VL region provided in any one of SEQ ID NOs: 31, 32, 35, 40, 41, 42, 43, 44, and 47.
  • the antibody comprises a combination of a VH chain region and a VL chain region selected from the combinations listed in Table 1.
  • the CD47 antibody or immunologically active fragment thereof comprises a VH complementarity determining region 1 (CDR1) sequence set forth in SEQ ID NO: 50, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, or SEQ ID NO: 66, a VH CDR2 sequence set forth in SEQ ID NO: 51, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, or SEQ ID NO: 76, a VII CDR3 sequence set forth in SEQ ID NO: 52 or SEQ ID NO: 77, a VL CDR1 sequence set forth in SEQ ID NO: 53, SEQ ID NO: 67, or SEQ ID NO: 68, a VL CDR2 sequence set forth in SEQ ID NO: 54
  • the antibody or immunologically active fragment thereof comprises a VII CDR1 sequence set forth in SEQ ID NO: 50, a VII CDR2 sequence set forth in SEQ ID NO: 51, a VH CDR3 sequence set forth in SEQ ID NO: 52, a VL CDR1 sequence set forth in SEQ ID NO: 53, a VL CDR2 sequence set forth in SEQ ID NO: 54, and a VL CDR3 sequence set forth in SEQ ID NO: 55.
  • the antibody or immunologically active fragment thereof comprises a VH CDR1 sequence set forth in SEQ ID NO: 50, a VH CDR2 sequence set forth in SEQ ID NO: 72, a VH CDR3 sequence set forth in SEQ ID NO: 52, a VL CDR1 set forth in SEQ ID NO: 53, a VL CDR2 sequence set forth in SEQ ID NO: 71, and a VL CDR3 sequence set forth in SEQ ID NO: 55.
  • the antibodies of the present invention bind to CD47 in a head to side orientation that positions the heavy chain near the membrane of CD47 expressing cell, while the light chain occludes the SIRP ⁇ binding site on CD47. In another embodiment, the antibodies of the present invention bind to CD47 in a head to side orientation that positions the light chain near the membrane of CD47 expressing cell, while the heavy chain occludes the SIRP ⁇ binding site on CD47.
  • the CD47 antibodies bind to an epitope that includes any one of amino acid residues 1-116 of CD47 when numbered in accordance with SEQ ID NO: 147 ( i.e ., SEQ ID NO: 48 excluding the signal sequence (amino acids 1-18)).
  • the antibodies may bind to an epitope that includes one or more of amino acid residues Q31, N32, T33, T34, E35, V36, Y37, V38, K39, W40, K41, F42, K43, G44, R45, D46, 147, Y48, T49, F50, D51, G52, A53, L54, N55, K56, S57, T58, V59, P60, T61, D62, F63, S64, S65, A66, K67, 168, E69, V70, S71, Q72, L73, L74, K75, G76, D77, A78, S79, L80, K81, M82, D83, K84, S85, D86, A87, V88, S89, H90, T91, G92, N93, Y94, T95, C96, E97, V98, T99, E100, L101, T102, R103, E104, G105, E106, T9,
  • the antibodies may bind to a discontinuous epitope that includes one or more of amino acid residues Y37, V38, K39, W40, K41, F42, K43, G44, R45, D46, I47, Y48, T49, F50, and D51 of CD47 when numbered in accordance with SEQ ID NO: 147.
  • the antibodies of the present invention bind to a discontinuous epitope comprising amino acids residues Y37, K39, K41, K43, G44, R45, D46, D51, H90, N93, E97, T99, E104, or E106 of CD47 when numbered in accordance with SEQ ID NO: 147.
  • the antibodies may bind to a discontinuous epitope that includes at least residues of the KGRD (SEQ ID NO: 56) loop (residues 43-46) of CD47 when numbered in accordance with SEQ ID NO: 147.
  • the antibodies of the present invention bind to a discontinuous epitope that includes at least residues Y37, K39, K41, the KGRD (SEQ ID NO: 56) loop (residues 43-46), D51, H90, N93, E97, T99, E104, and E106 of CD47 when numbered in accordance with SEQ ID NO: 147.
  • the antibodies of the present invention bind to a discontinuous epitope that includes residues Y37, K39, K41, the KGRD (SEQ ID NO: 56) loop (residues 43-46), D51, H90, N93, E97, T99, E104, and E106 of CD47 when numbered in accordance with SEQ ID NO: 147.
  • the VH region of the CD47 antibodies described herein is primarily involved in binding to the KGRD (SEQ ID NO: 56) loop of CD47.
  • the unique epitope to which antibodies of the present invention bind is on the side of CD47.
  • the orientation of the VH domain of the CD47 antibodies described herein in a membrane proximal position is a critical feature of these antibodies that prevents cellular clumping, e.g ., red blood cell hemagglutination, by constraining the antibodies such that they cannot bridge to CD47 molecules on adjacent cells.
  • VK domain of the CD47 antibodies described herein interacts with apical residues such as Y37, T102, and E104, which are involved in SIRP ⁇ binding, it is primarily the VK domain that physically precludes SIRP ⁇ binding to CD47.
  • polypeptide comprising amino acids residues Y37, K39, K41, K43, G44, R45, D46, D51, H90, N93, E97, T99, E104, and E106 of CD47 when numbered in accordance with SEQ ID NO: 147. Also disclosed is a polypeptide comprising any one of amino acid residues 1-116 of CD47 when numbered in accordance with SEQ ID NO: 147.
  • the polypeptide comprises one or more of amino acid residues Q31, N32, T33, T34, E35, V36, Y37, V38, K39, W40, K41, F42, K43, G44, R45, D46,147, Y48, T49, F50, D51, G52, A53, L54, N55, K56, S57, T58, V59, P60, T61, D62, F63, S64, S65, A66, K67, I68, E69, V70, S71, Q72, L73, L74, K75, G76, D77, A78, S79, L80, K81, M82, D83, K84, S85, D86, A87, V88, S89, H90, T91, G92, N93, Y94, T95, C96, E97, V98, T99, E100, L101, T102, R103, E104, G105, E106, T107, I108, I109,
  • the invention also provides an antibody or an immunologically active fragment thereof of the invention for use in methods of alleviating a symptom of a cancer or other neoplastic condition by administering to a subject in need thereof one or more monoclonal antibodies that bind to CD47 or an immunologically active fragment thereof, wherein the antibody does not cause a significant level of hemagglutination of red blood cells after administration.
  • the antibody is administered in an amount sufficient to alleviate the symptom of the cancer or other neoplastic condition in the subject.
  • the subject is a human.
  • the antibody is chimeric, humanized, or fully human.
  • the antibody binds to human CD47.
  • the antibody or immunologically active fragment thereof prevents CD47 from interacting with SIRP ⁇ .
  • the antibody or immunologically active fragment thereof is an IgG isotype selected from the group consisting of IgG1 isotype, IgG2 isotype, IgG3 isotype, and IgG4 isotype.
  • the antibody or immunologically active fragment thereof is an IgG isotype selected from IgG4P and IgG4PE.
  • the CD47 antibodies described herein are used in conjunction with one or more additional agents or a combination of additional agents.
  • Suitable additional agents include current pharmaceutical and/or surgical therapies for an intended application, such as, for example, cancer.
  • the CD47 antibodies can be used in conjunction with one or more additional chemotherapeutic or anti-neoplastic agents.
  • the additional chemotherapeutic agent is radiotherapy.
  • the chemotherapeutic agent is a cell death-inducing agent.
  • the chemotherapeutic agent induces a loss of phospholipid asymmetry across the plasma membrane, for example causes cell surface exposure of phosphatidylserine (PS).
  • PS phosphatidylserine
  • the chemotherapeutic agent induces endoplasmic reticulum (ER) stress.
  • the chemotherapeutic agent is a proteasome inhibitor.
  • the chemotherapeutic agent induces the translocation of ER proteins to the cell surface.
  • the chemotherapeutic agent induces the translocation and cell surface exposure of calreticulin.
  • the CD47 antibody and additional agent are formulated into a single therapeutic composition, and the CD47 antibody and additional agent are administered simultaneously.
  • the CD47 antibody and additional agent are separate from each other, e.g ., each is formulated into a separate therapeutic composition, and the CD47 antibody and the additional agent are administered simultaneously, or the CD47 antibody and the additional agent are administered at different times during a treatment regimen.
  • the CD47 antibody is administered prior to the administration of the additional agent, the CD47 antibody is administered subsequent to the administration of the additional agent, or the CD47 antibody and the additional agent are administered in an alternating fashion.
  • the CD47 antibody and additional agent are administered in single doses or in multiple doses.
  • the antibodies of the invention have a variety of uses.
  • the antibodies of the invention are used as therapeutic agents, as reagents in diagnostic kits or as diagnostic tools, or as reagents in competition assays to generate therapeutic reagents.
  • the present invention provides monoclonal antibodies that specifically bind CD47, including human CD47. These antibodies are collectively referred to herein as CD47 antibodies.
  • CD47 a multi-spanning transmembrane receptor belonging to the immunoglobulin superfamily, interacts with SIRP ⁇ (signal-regulatory-protein ⁇ ) on macrophages and thereby dampens phagocytosis. Cancer cells that co-opt this pathway evade phagocytosis. As described in detail below, this is a new mechanism of tumor immune avoidance, and therapeutically targeting CD47 has widespread application in numerous cancers.
  • CD47 correlates with worse clinical outcomes in many distinct malignancies including Non-Hodgkin Lymphoma (NHL), Acute Lymphocytic Leukemia (ALL), Acute Myelogenous leukemia (AML), ovarian cancer, glioma, glioblastoma, etc.
  • NHL Non-Hodgkin Lymphoma
  • ALL Acute Lymphocytic Leukemia
  • AML Acute Myelogenous leukemia
  • ovarian cancer glioma, glioblastoma, etc.
  • CD47 has been identified as a cancer stem cell marker in both leukemias and solid tumors ( Jaiswal et al., 2009 Cell, 138(2): 271-85 ; Chan et al., 2009 Proc Natl Acad Sci USA, 106(33): 14016-21 ; Chan et al., 2010 Curr Opin Urol, 20(5): 393-7 ; Majeti R et al., 2011 Oncogene, 30(9): 1009-19 ).
  • CD47 blocking antibodies have demonstrated anti-tumor activity multiple in vivo tumor models. Furthermore, these antibodies have been shown to synergize with other therapeutic antibodies including Rituxan® and Herceptin® in tumor models. Blocking the interaction of CD47 with SIRP ⁇ is capable of promoting phagocytosis of CD47 expressing cells by macrophages (reviewed in Chao et al., 2012 Curr Opin Immunol, 24(2): 225-32 ). Mice lacking CD47 are markedly resistant to radiation therapy, suggesting a role for targeting CD47 in combination with radiotherapy ( Isenberg et al., 2008 Am J Pathol, 173(4): 1100-1112 ; Maxhimer et al., 2009 Sci Transl Med, 1(3): 3ra7 ). Furthermore, syngeneic tumor models in these mice display decreased bone metastasis compared wild-type mice ( Uluçkan et al., 2009 Cancer Res, 69(7): 3196-204 ).
  • CD47 antibodies have been reported to cause hemagglutination of human erythrocytes. Hemagglutination is an example of a homotypic interaction, wherein two CD47 expressing cells are caused to aggregate or clump when treated with a bivalent CD47 binding entity.
  • the CD47 antibody, MABL as a full IgG or F(ab') 2 , has been reported to cause hemagglutination of erythrocytes, and, only when MABL was altered into an scFv or bivalent scFv, was this effect mitigated.
  • CD47 antibodies an important characteristic of CD47 antibodies is the ability to block the interaction of CD47 and SIRP ⁇ in order to promote the phagocytosis of CD47 expressing cells by macrophages.
  • Many existing CD47 antibodies block SIRP ⁇ ; however, prior to the invention described herein, existing antibodies that blocked SIRP ⁇ caused the side effect of hemagglutination, which, as described above, is undesirable.
  • Other existing antibodies, such as 2D3, do not cause hemagglutination; however, these antibodies also do not block SIRP ⁇ , rendering them ineffective in the promotion of phagocytosis.
  • the present invention provides an isolated monoclonal antibody or immunologically active fragment thereof that binds to human CD47, wherein the antibody or immunologically active fragment thereof binds to a discontinuous epitope on CD47, wherein the discontinuous epitope comprises amino acids residues Y37, K39, K41, K43, G44, R45, D46, D51, H90, N93, E97, T99, E104, and E106 of CD47 when numbered in accordance with SEQ ID NO: 147, and wherein the antibody or immunologically active fragment thereof prevents CD47 from interacting with signal-regulatory-protein ⁇ (SIRP ⁇ ) and does not cause a significant level of agglutination of cells after administration.
  • SIRP ⁇ signal-regulatory-protein ⁇
  • the antibody or immunologically active fragment thereof is chimeric or humanized.
  • the antibody or immunologically active fragment thereof promotes macrophage-mediated phagocytosis of a CD47-expressing cell.
  • the antibody or immunologically active fragment thereof is an IgG isotype selected from the group consisting of IgG 1 isotype, IgG2 isotype, IgG3 isotype, and IgG4 isotype.
  • the antibody or immunologically active fragment thereof is an IgG isotype selected from IgG4P and IgG4PE.
  • the antibody or immunologically active fragment thereof comprises:
  • the antibody or immunologically active fragment thereof comprises:
  • the present invention further provides a pharmaceutical composition comprising the antibody or immunologically active fragment thereof of the invention and a carrier.
  • the present invention further provides an antibody or an immunologically active fragment thereof of the invention for use in a method of alleviating a symptom of a cancer or other neoplastic condition in a subject.
  • the subject is a human.
  • the method further comprises administering chemotherapy.
  • the method further comprises administering radiotherapy.
  • the CD47 antibodies of the present invention avoid the undesirable effect of hemagglutination, thereby increasing the efficacy of therapeutically targeting CD47, and maintain the ability to block the interaction of CD47 with SIRP ⁇ , thereby promoting phagocytosis of CD47 expressing cells.
  • the full IgG CD47 antibodies of the present invention e.g., 2A1 and its humanized derivatives including those provided in Table 1
  • the CD47 antibodies of the invention do not hemagglutinate RBCs at a significant level.
  • Described herein are the first CD47 antibodies in a full IgG format that block SIRP ⁇ and do not cause a significant level of hemagglutination.
  • the antibodies of the invention e.g., the 2A1 antibody and its humanized derivatives
  • the CD47 antibodies of the invention exhibit numerous desirable characteristics, such as, by way of non-limiting example, potent blocking of the interaction between CD47 and its ligand SIRP ⁇ , without causing a significant level of or otherwise modulating hemagglutination of erythrocytes, as well as potent anti-tumor activity.
  • the CD47 antibodies of the invention block at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 95%, or at least 99% of the interaction between CD47 and SIRP ⁇ as compared to the level of interaction between CD47 and SIRP ⁇ in the absence of the CD47 antibody described herein.
  • the CD47 antibodies of the invention do not cause a significant level of agglutination of cells, e.g., the CD47 antibodies of the invention do not cause a significant level of hemagglutination of red blood cells.
  • the level of agglutination in the presence of the CD47 antibodies of the invention is reduced by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 99% compared to the level of agglutination in the presence existing CD47 antibodies.
  • the CD47 antibodies of the invention do not cause a significant level of agglutination if the level of agglutination in the presence of the CD47 antibodies of the invention is reduced by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 99% compared to the level of agglutination in the presence of CD47 antibody, 1B4, which comprises a variable heavy and variable light chain sequence provided in SEQ ID NO: 80 and SEQ ID NO: 81, respectively.
  • the antibodies of the present invention are also significantly more potent in tumor models compared to antibodies known in the art.
  • the ability of macrophages to phagocytose tumor cells in the presence of CD47 antibodies of the invention is increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 99% compared to the ability of macrophages to phagocytose tumor cells in the presence of existing CD47 antibodies.
  • the level of agglutination e.g., the level of hemagglutination of RBCs.
  • the level of hemagglutination is ascertained by measuring the area of an RBC dot after performing a hemagglutination assay in the presence of the CD47 antibodies of the invention, as described in the Examples below. In some cases, the area of the RBC dot in the presence of the CD47 antibody of the invention is compared to the area of the RBC dot in the absence of a CD47 antibody, i.e., in the presence of zero hemagglutination.
  • hemagglutination is quantified relative to a baseline control.
  • a larger RBC dot area corresponds to a higher level of hemagglutination.
  • densitometry of the RBC dot may also be utilized to quantitate hemagglutination.
  • the CD47 antibodies of the invention bind to human CD47 and block its interaction with SIRP ⁇ ( Figures 1B , 3 , and 7J ). These antibodies do not cause a significant level of hemagglutination of human erythrocytes ( Figure 4 ). These antibodies are capable of promoting phagocytosis of tumor cells by macrophages ( Figure 9 ). Furthermore, the CD47 antibodies display potent anti-tumor activity in a mouse model of human lymphoma ( Figure 10 ). Thus, the CD47 antibodies of the invention circumvent a major limiting factor for the therapeutic targeting CD47. Accordingly, the CD47 antibodies of the invention stand to be of great importance in treatment a multitude of cancers.
  • Antibodies of the invention that specifically bind human CD47, block, inhibit, disrupt or otherwise modulate the interaction between human CD47 and human SIRP ⁇ , without causing a significant level of or otherwise modulating hemagglutination of erythrocytes.
  • the antibodies of the present invention bind to a CD47 epitope with an equilibrium binding constant (K d ) of ⁇ 1 ⁇ M, e.g., ⁇ 100 nM, preferably ⁇ 10 nM, and more preferably ⁇ 1 nM.
  • K d equilibrium binding constant
  • the CD47 antibodies provided herein exhibit a K d in the range approximately between ⁇ 1 nM to about 1 pM.
  • the CD47 antibodies of the invention serve to modulate, block, inhibit, reduce, antagonize, neutralize or otherwise interfere with the functional activity of the widely distributed CD47.
  • Functional activities of CD47 include for example, signaling via the interaction with SIRP ⁇ , modulating, e.g., increasing, intracellular calcium concentration upon cell adhesion to extracellular matrix, interacting with the C-terminal cell binding domain of thrombospondin, interacting with fibrinogen, and interacting with various integrins.
  • the CD47 antibodies completely or partially inhibit CD47 functional activity by partially or completely modulating, blocking, inhibiting, reducing antagonizing, neutralizing, or otherwise interfering with the binding of CD47 to SIRP ⁇ .
  • the CD47 antibodies are considered to completely modulate, block, inhibit, reduce, antagonize, neutralize or otherwise interfere with CD47 functional activity when the level of CD47 functional activity in the presence of CD47 antibody is decreased by at least 95%, e.g., by 96%, 97%, 98%, 99% or 100% as compared to the level of CD47 functional activity in the absence of binding with a CD47 antibody described herein.
  • the CD47 antibodies are considered to significantly block, inhibit, reduce, antagonize, neutralize or otherwise interfere with CD47 functional activity when the level of CD47 activity in the presence of the CD47 antibody is decreased by at least 50%, e.g., 55%, 60%, 75%, 80%, 85% or 90% as compared to the level of CD47 activity in the absence of binding with a CD47 antibody described herein.
  • the CD47 antibodies are considered to partially modulate, block, inhibit, reduce, antagonize, neutralize or otherwise interfere with CD47 functional activity when the level of CD47 activity in the presence of the CD47 antibody is decreased by less than 95%, e.g., 10%, 20%, 25%, 30%, 40%, 50%, 60%, 75%, 80%, 85% or 90% as compared to the level of CD47 activity in the absence of binding with a CD47 antibody described herein.
  • CD47 integrin-associated protein (IAP), ovarian cancer antigen OA3, Rh-related antigen and MER6 are synonymous and may be used interchangeably.
  • red blood cell(s) and erythrocyte(s) are synonymous and used interchangeably herein.
  • agglutination refers to cellular clumping
  • hemagglutination refers to clumping of a specific subset of cells, i.e., red blood cells.
  • hemagglutination is a type of agglutination.
  • antibody refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen.
  • Ig immunoglobulin
  • bind or “immunoreacts with” "or directed against” is meant that the antibody reacts with one or more antigenic determinants of the desired antigen and does not react with other polypeptides or binds at much lower affinity (K d > 10 -6 ).
  • Antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, dAb (domain antibody), single chain, Fab, Fab and F(ab') 2 fragments, F v , scFvs, and an Fab expression library.
  • the basic antibody structural unit is known to comprise a tetramer.
  • Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light” (about 25 kDa) and one "heavy" chain (about 50-70 kDa).
  • the amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
  • the carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function.
  • antibody molecules obtained from humans relate to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG 1 , IgG 2 , and others.
  • the light chain may be a kappa chain or a lambda chain.
  • MAb monoclonal antibody
  • CDRs complementarity determining regions
  • antibody molecules obtained from humans relate to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG 1 , IgG 2 , and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain.
  • antigen binding site refers to the part of the immunoglobulin molecule that participates in antigen binding.
  • the antigen binding site is formed by amino acid residues of the N-terminal variable ("V") regions of the heavy ("H") and light (“L”) chains.
  • V N-terminal variable
  • H heavy
  • L light
  • FR framework regions
  • the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three-dimensional space to form an antigen-binding surface.
  • the antigen-binding surface is complementary to the three-dimensional surface of a bound antigen, and the three hypervariable regions of each of the heavy and light chains are referred to as "complementarity-determining regions," or "CDRs.”
  • CDRs complementarity-determining regions
  • epitopic determinants include any protein determinant capable of specific binding to an immunoglobulin or fragment thereof, or a T-cell receptor.
  • epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
  • An antibody is said to specifically bind an antigen when the dissociation constant is ⁇ 1 ⁇ M; e.g., ⁇ 100 nM, preferably ⁇ 10 nM and more preferably ⁇ 1 nM.
  • immunological binding refers to the non-covalent interactions of the type which occur between an immunoglobulin molecule and an antigen for which the immunoglobulin is specific.
  • the strength, or affinity of immunological binding interactions can be expressed in terms of the dissociation constant (K d ) of the interaction, wherein a smaller K d represents a greater affinity.
  • Immunological binding properties of selected polypeptides can be quantified using methods well known in the art. One such method entails measuring the rates of antigen-binding site/antigen complex formation and dissociation, wherein those rates depend on the concentrations of the complex partners, the affinity of the interaction, and geometric parameters that equally influence the rate in both directions.
  • both the "on rate constant” (k on ) and the “off rate constant” (k off ) can be determined by calculation of the concentrations and the actual rates of association and dissociation. ( See Nature 361:186-87 (1993 )).
  • the ratio of k off /k on enables the cancellation of all parameters not related to affinity, and is equal to the dissociation constant K d . ( See, generally, Davies et al. (1990) Annual Rev Biochem 59:439-473 ).
  • An antibody of the present invention is said to specifically bind to CD47, when the equilibrium binding constant (K d ) is ⁇ 1 ⁇ M, preferably ⁇ 100 nM, more preferably ⁇ 10 nM, and most preferably ⁇ 100 pM to about 1 pM, as measured by assays such as radioligand binding assays, surface plasmon resonance (SPR), flow cytometry binding assay, or similar assays known to those skilled in the art.
  • K d equilibrium binding constant
  • isolated polynucleotide shall mean a polynucleotide of genomic, cDNA, or synthetic origin or some combination thereof, which by virtue of its origin the "isolated polynucleotide” (1) is not associated with all or a portion of a polynucleotide in which the "isolated polynucleotide” is found in nature, (2) is operably linked to a polynucleotide which it is not linked to in nature, or (3) does not occur in nature as part of a larger sequence.
  • isolated protein means a protein of cDNA, recombinant RNA, or synthetic origin or some combination thereof, which by virtue of its origin, or source of derivation, the "isolated protein” (1) is not associated with proteins found in nature, (2) is free of other proteins from the same source, e.g., free of marine proteins, (3) is expressed by a cell from a different species, or (4) does not occur in nature.
  • polypeptide is used herein as a generic term to refer to native protein, fragments, or analogs of a polypeptide sequence. Hence, native protein fragments, and analogs are species of the polypeptide genus.
  • naturally-occurring refers to the fact that an object can be found in nature.
  • a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory or otherwise is naturally-occurring.
  • operably linked refers to positions of components so described are in a relationship permitting them to function in their intended manner.
  • a control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
  • control sequence refers to polynucleotide sequences which are necessary to effect the expression and processing of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence in eukaryotes, generally, such control sequences include promoters and transcription termination sequence.
  • control sequences is intended to include, at a minimum, all components whose presence is essential for expression and processing, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.
  • polynucleotide refers to a polymeric boron of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide.
  • the term includes single and double stranded forms of DNA.
  • oligonucleotide includes naturally occurring, and modified nucleotides linked together by naturally occurring, and non-naturally occurring oligonucleotide linkages.
  • Oligonucleotides are a polynucleotide subset generally comprising a length of 200 bases or fewer. Preferably oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 bases in length. Oligonucleotides are usually single stranded, e.g., for probes, although oligonucleotides may be double stranded, e.g., for use in the construction of a gene mutant. Oligonucleotides of the invention are either sense or antisense oligonucleotides.
  • nucleotides includes deoxyribonucleotides and ribonucleotides.
  • modified nucleotides includes nucleotides with modified or substituted sugar groups and the like.
  • oligonucleotide linkages includes Oligonucleotides linkages such as phosphorothioate, phosphorodithioate, phosphoroselerloate, phosphorodiselenoate, phosphoroanilothioate, phoshoraniladate, phosphoronmidate, and the like. See e.g., LaPlanche et al. Nucl. Acids Res.
  • oligonucleotide can include a label for detection, if desired.
  • the term "selectively hybridize” referred to herein means to detectably and specifically bind.
  • Polynucleotides, oligonucleotides and fragments thereof in accordance with the invention selectively hybridize to nucleic acid strands under hybridization and wash conditions that minimize appreciable amounts of detectable binding to nonspecific nucleic acids.
  • High stringency conditions can be used to achieve selective hybridization conditions as known in the art and discussed herein.
  • the nucleic acid sequence homology between the polynucleotides, oligonucleotides, and fragments of the invention and a nucleic acid sequence of interest will be at least 80%, and more typically with preferably increasing homologies of at least 85%, 90%, 95%, 99%, and 100%.
  • Two amino acid sequences are homologous if there is a partial or complete identity between their sequences. For example, 85% homology means that 85% of the amino acids are identical when the two sequences are aligned for maximum matching. Gaps (in either of the two sequences being matched) are allowed in maximizing matching gap lengths of 5 or less are preferred with 2 or less being more preferred.
  • two protein sequences or polypeptide sequences derived from them of at least 30 amino acids in length
  • the two sequences or parts thereof are more preferably homologous if their amino acids are greater than or equal to 50% identical when optimally aligned using the ALIGN program.
  • the term "corresponds to” is used herein to mean that a polynucleotide sequence is homologous ( i.e., is identical, not strictly evolutionarily related) to all or a portion of a reference polynucleotide sequence, or that a polypeptide sequence is identical to a reference polypeptide sequence.
  • the term “complementary to” is used herein to mean that the complementary sequence is homologous to all or a portion of a reference polynucleotide sequence.
  • the nucleotide sequence "TATAC” corresponds to a reference sequence “TATAC” and is complementary to a reference sequence "GTATA”.
  • reference sequence is a defined sequence used as a basis for a sequence comparison a reference sequence may be a subset of a larger sequence, for example, as a segment of a full-length cDNA or gene sequence given in a sequence listing or may comprise a complete cDNA or gene sequence. Generally, a reference sequence is at least 18 nucleotides or 6 amino acids in length, frequently at least 24 nucleotides or 8 amino acids in length, and often at least 48 nucleotides or 16 amino acids in length.
  • two polynucleotides or amino acid sequences may each (1) comprise a sequence ( i.e., a portion of the complete polynucleotide or amino acid sequence) that is similar between the two molecules, and (2) may further comprise a sequence that is divergent between the two polynucleotides or amino acid sequences
  • sequence comparisons between two (or more) molecules are typically performed by comparing sequences of the two molecules over a "comparison window" to identify and compare local regions of sequence similarity.
  • a “comparison window”, as used herein, refers to a conceptual segment of at least 18 contiguous nucleotide positions or 6 amino acids wherein a polynucleotide sequence or amino acid sequence may be compared to a reference sequence of at least 18 contiguous nucleotides or 6 amino acid sequences and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions, deletions, substitutions, and the like (i.e., gaps) of 20 percent or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences.
  • Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman Adv. Appl. Math.
  • sequence identity means that two polynucleotide or amino acid sequences are identical (i.e., on a nucleotide-by-nucleotide or residue-by-residue basis) over the comparison window.
  • percentage of sequence identity is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U or I) or residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window ( i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.
  • substantially identical denotes a characteristic of a polynucleotide or amino acid sequence, wherein the polynucleotide or amino acid comprises a sequence that has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison window of at least 18 nucleotide (6 amino acid) positions, frequently over a window of at least 24-48 nucleotide (8-16 amino acid) positions, wherein the percentage of sequence identity is calculated by comparing the reference sequence to the sequence which may include deletions or additions which total 20 percent or less of the reference sequence over the comparison window.
  • the reference sequence may be a subset of a larger sequence.
  • Examples of unconventional amino acids include: 4 hydroxyproline, ⁇ -carboxyglutamate, ⁇ -N,N,N-trimethyllysine, ⁇ -N-acetyllysine, O-phosphoserine, N- acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, ⁇ -N-methylarginine, and other similar amino acids and imino acids (e.g., 4- hydroxyproline).
  • the left-hand direction is the amino terminal direction and the right-hand direction is the carboxy-terminal direction, in accordance with standard usage and convention.
  • the left-hand end of single- stranded polynucleotide sequences is the 5' end the left-hand direction of double-stranded polynucleotide sequences is referred to as the 5' direction.
  • the direction of 5' to 3' addition of nascent RNA transcripts is referred to as the transcription direction sequence regions on the DNA strand having the same sequence as the RNA and which are 5' to the 5' end of the RNA transcript are referred to as "upstream sequences", sequence regions on the DNA strand having the same sequence as the RNA and which are 3' to the 3' end of the RNA transcript are referred to as "downstream sequences".
  • the term "substantial identity” means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 80 percent sequence identity, preferably at least 90 percent sequence identity, more preferably at least 95 percent sequence identity, and most preferably at least 99 percent sequence identity.
  • residue positions which are not identical differ by conservative amino acid substitutions.
  • Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains.
  • a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide- containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur- containing side chains is cysteine and methionine.
  • Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine valine, glutamic- aspartic, and asparagine-glutamine.
  • amino acid sequences of antibodies or immunoglobulin molecules are contemplated as being encompassed by the present invention, providing that the variations in the amino acid sequence maintain at least 75%, more preferably at least 80%, 90%, 95%, and most preferably 99%.
  • conservative amino acid replacements are contemplated. Conservative replacements are those that take place within a family of amino acids that are related in their side chains.
  • amino acids are generally divided into families: (1) acidic amino acids are aspartate, glutamate; (2) basic amino acids are lysine, arginine, histidine; (3) non-polar amino acids are alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, and (4) uncharged polar amino acids are glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine.
  • the hydrophilic amino acids include arginine, asparagine, aspartate, glutamine, glutamate, histidine, lysine, serine, and threonine.
  • the hydrophobic amino acids include alanine, cysteine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, tyrosine and valine.
  • Other families of amino acids include (i) serine and threonine, which are the aliphatic-hydroxy family; (ii) asparagine and glutamine, which are the amide containing family; (iii) alanine, valine, leucine and isoleucine, which are the aliphatic family; and (iv) phenylalanine, tryptophan, and tyrosine, which are the aromatic family.
  • Structural and functional domains can be identified by comparison of the nucleotide and/or amino acid sequence data to public or proprietary sequence databases.
  • computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains that occur in other proteins of known structure and/or function. Methods to identify protein sequences that fold into a known three-dimensional structure are known. Bowie et al. Science 253:164 (1991 ).
  • sequence motifs and structural conformations that may be used to define structural and functional domains in accordance with the invention.
  • Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinities, and (4) confer or modify other physicochemical or functional properties of such analogs.
  • Analogs can include various muteins of a sequence other than the naturally-occurring peptide sequence. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally- occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts.
  • a conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to break a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence).
  • Examples of art-recognized polypeptide secondary and tertiary structures are described in Proteins, Structures and Molecular Principles (Creighton, Ed., W. H. Freeman and Company, New York (1984 )); Introduction to Protein Structure (C. Branden and J. Tooze, eds., Garland Publishing, New York, N.Y. (1991 )); and Thornton et al. Nature 354:105 (1991 ).
  • polypeptide fragment refers to a polypeptide that has an amino terminal and/or carboxy-terminal deletion, but where the remaining amino acid sequence is identical to the corresponding positions in the naturally-occurring sequence deduced, for example, from a full length cDNA sequence. Fragments typically are at least 5, 6, 8 or 10 amino acids long, preferably at least 14 amino acids long' more preferably at least 20 amino acids long, usually at least 50 amino acids long, and even more preferably at least 70 amino acids long.
  • analog refers to polypeptides which are comprised of a segment of at least 25 amino acids that has substantial identity to a portion of a deduced amino acid sequence and which has specific binding to CD47, under suitable binding conditions.
  • polypeptide analogs comprise a conservative amino acid substitution (or addition or deletion) with respect to the naturally- occurring sequence.
  • Analogs typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, and can often be as long as a full-length naturally-occurring polypeptide.
  • Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs with properties analogous to those of the template peptide. These types of non-peptide compound are termed "peptide mimetics" or "peptidomimetics”. Fauchere, J. Adv. Drug Res. 15:29 (1986 ), Veber and Freidinger TINS p.392 (1985 ); and Evans et al. J. Med. Chem. 30:1229 (1987 ). Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to therapeutically useful peptides may be used to produce an equivalent therapeutic or prophylactic effect.
  • a paradigm polypeptide i.e., a polypeptide that has a biochemical property or pharmacological activity
  • Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type may be used to generate more stable peptides.
  • constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known in the art ( Rizo and Gierasch Ann. Rev. Biochem. 61:387 (1992 )); for example, by adding internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.
  • agent is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials.
  • label refers to incorporation of a detectable marker, e.g., by incorporation of a radiolabeled amino acid or attachment to a polypeptide of biotinyl moieties that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or calorimetric methods). In certain situations, the label or marker can also be therapeutic. Various methods of labeling polypeptides and glycoproteins are known in the art and may be used.
  • labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g., 3 II, 14 C, 15 N, 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131 I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels ( e .
  • radioisotopes or radionuclides e.g., 3 II, 14 C, 15 N, 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131 I
  • fluorescent labels e.g., FITC, rhodamine, lanthanide phosphors
  • enzymatic labels e .
  • labels are attached by spacer arms of various lengths to reduce potential steric hindrance.
  • pharmaceutical agent or drug refers to a chemical compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient.
  • anti-plastic agent is used herein to refer to agents that have the functional property of inhibiting a development or progression of a neoplasm in a human, particularly a malignant (cancerous) lesion, such as a carcinoma, sarcoma, lymphoma, or leukemia. Inhibition of metastasis is frequently a property of antineoplastic agents.
  • substantially pure means an object species is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all macromolecular species present.
  • a substantially pure composition will comprise more than about 80 percent of all macromolecular species present in the composition, more preferably more than about 85%, 90%, 95%, and 99%.
  • the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.
  • Monoclonal antibodies of the invention have the ability to bind CD47, to inhibit the binding of SIRP ⁇ to CD47, decrease CD47-SIRP ⁇ -mediated signaling, promote phagocytosis, and to inhibit tumor growth and/or migration. Inhibition is determined, for example, using the cellular assay described herein in the Examples.
  • Exemplary antibodies of the invention include the 2A1 antibody, the chimeric version of 2A1, and humanized variants of 2A1.
  • Exemplary antibodies of the invention include an antibody having a variable heavy (VII) chain selected from SEQ ID NOs: 5-30, and having a variable light (VL) chain selected from SEQ ID NOs: 31-47.
  • exemplary antibodies include those provided in Table 1. Table 1.
  • antibodies that bind to the same epitope as the CD47 antibodies described herein are antibodies that bind to the same epitope as the CD47 antibodies described herein.
  • antibodies may specifically bind to an epitope that includes one or more amino acid residues on human CD47 (see e.g., GenBank Accession No. Q08722.1).
  • amino acid sequence of an exemplary human CD47 is provided below (GenBank Accession No. Q08722.1 (GI:1171879).
  • the signal sequence (amino acids 1-18) is underlined.
  • amino acid sequence of an exemplary human CD47 excluding the signal sequence is provided below.
  • amino acid sequence of an exemplary human CD47-IgV domain is provided below:
  • Exemplary monoclonal antibodies of the invention include, for example, humanized antibodies having a variable heavy chain region (VH) and/or variable light (VL) chain region shown in the sequences below.
  • VH variable heavy chain region
  • VL variable light chain region
  • VH CDRI is GFNIKDYYLH (SEQ ID) NO: 50), GYTFTYYYLH (SEQ ID NO: 57), GFTFTYYYLH (SEQ ID NO: 58), GYNFTYYYLH (SEQ ID NO: 59), GYTITYYYLH (SEQ ID NO: 60), GYTFKYYYLH (SEQ ID NO: 61), GYTFTDYYLH (SEQ ID NO: 62), GFTFTDYYLH (SEQ ID NO: 63), GFTITYYLH (SEQ ID NO: 64), GYTFKDYYLH (SEQ ID NO: 65), or GFTFKDYYLH (SEQ ID NO: 66).
  • the amino acid sequence of VH CDR2 is WIDPDNGDTE (SEQ ID NO: 51), WIDPDQGDTE (SEQ ID NO: 72), WIDPDYGDTE (SEQ ID NO: 73), WIDPDSGDTE (SEQ ID NO: 74), WIDPDNADTE (SEQ ID NO: 75), or WIDPDNTDTE (SEQ ID NO: 76).
  • the amino acid sequence of VII CDR3 is NAAYGSSSYPMDY (SEQ ID NO: 52) or NAAYGSSPYPMDY (SEQ ID NO: 77).
  • VL chain regions of the CD47 antibodies are provided below.
  • the CDRs of the VL chain of the CD47 antibodies are highlighted below.
  • the amino acid sequence of VL CDR1 is KASQDIIIRYLS (SEQ ID NO: 53), RASQDIIIRYLA (SEQ ID NO: 67), or RARQGIIIRYLS (SEQ ID NO: 68).
  • the amino acid sequence of VL CDR2 is RANRLVD (SEQ ID NO: 54), RANRLQS (SEQ ID NO: 69), RANRRAT (SEQ ID NO: 70), or RANRLVS (SEQ ID NO: 71).
  • the amino acid sequence of VL CDR3 is LQYDEFPYT (SEQ ID NO: 55).
  • the CD47 antibodies described herein comprise a variable heavy chain region selected from SEQ ID NOs: 5-30 and a variable light chain region selected from SEQ ID NOs: 31-47.
  • An exemplary CD47 antibody comprises a variable heavy chain region set forth in SEQ ID NO: 5 and a variable light chain region set forth in SEQ ID NO: 31; a variable heavy chain region set forth in SEQ ID NO: 7 and a variable light chain region set forth in SEQ ID NO: 35; a variable heavy chain region set forth in SEQ ID NO: 11 and a variable light chain region set forth in SEQ ID NO: 42, a variable heavy chain region set forth in SEQ ID NO: 5 and a variable light chain region set forth in SEQ ID NO: 32, a variable heavy chain region set forth in SEQ ID NO: 7 and a variable light chain region set forth in SEQ ID NO: 33, a variable heavy chain region set forth in SEQ ID NO: 7 and a variable light chain region set forth in SEQ ID NO: 34, a variable heavy chain region set forth in S
  • the CD47 antibodies described herein comprise any one of the VII regions provided in SEQ ID NOs: 5-30 paired with any one of the VL regions provided in SEQ ID NOs: 31-47. Specifically, the CD47 antibodies described herein comprise any one of the VH regions provided in SEQ ID NOs: 5, 7, 8, 11, 15-17, 20-22, and 27-30 paired with any one of the VL regions provided in SEQ ID NOs: 31-39, 42, 43, 44, and 47.
  • the CD47 antibodies described herein comprise any one of the VH CDR1 regions provided in SEQ ID NO: 50, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, and SEQ ID NO: 66, any one of the VII CDR2 regions provided in SEQ ID NO: 51, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, and SEQ ID NO: 76, any one of the VII CDR3 regions provided in SEQ ID NO: 52 and SEQ ID NO: 77, any one of the VL CDR1 regions provided in SEQ ID NO: 53, SEQ ID NO: 67, and SEQ ID NO: 68, any one of the VL CDR2 regions provided in SEQ ID NO: 54, SEQ ID NO: 69, SEQ ID
  • a monoclonal antibody has the same specificity as a monoclonal antibody of the invention (e.g., the 2A1 antibody, or an antibody having a variable heavy chain selected from SEQ ID NOs: 5-31, and a variable light chain selected from SEQ ID NOs: 31-47) by ascertaining whether the former prevents the latter from binding to CD47. If the monoclonal antibody being tested competes with the monoclonal antibody of the invention, as shown by a decrease in binding by the monoclonal antibody of the invention, then the two monoclonal antibodies bind to the same, or a closely related, epitope.
  • An alternative method for determining whether a monoclonal antibody has the specificity of monoclonal antibody of the invention is to pre-incubate the monoclonal antibody of the invention with soluble CD47 protein (with which it is normally reactive), and then add the monoclonal antibody being tested to determine if the monoclonal antibody being tested is inhibited in its ability to bind CD47. If the monoclonal antibody being tested is inhibited then, in all likelihood, it has the same, or functionally equivalent, epitopic specificity as the monoclonal antibody of the invention.
  • Screening of monoclonal antibodies of the invention can be also carried out, e.g., by measuring CD47- and/or CD47/SIRP ⁇ -mediated signaling, and determining whether the test monoclonal antibody is able to modulate, block, inhibit, reduce, antagonize, neutralize or otherwise interfere with CD47- and/or CD47/SIRP ⁇ -mediated signaling.
  • These assays can include competitive binding assays. Additionally, these assays can measure a biologic readout, for example the ability to promote phagocytosis of a CD47 expressing cell by a macrophage, as is described in Example 9 ( Figure 9 ).
  • Fully human antibodies are antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies” or “fully human antibodies” herein. Human monoclonal antibodies are prepared, for example, using the procedures described in the Examples provided below.
  • Human monoclonal antibodies can be also prepared by using the trioma technique; the human B-cell hybridoma technique ( see Kozbor, et al., 1983 Immunol Today 4: 72 ); and the EBV hybridoma technique to produce human monoclonal antibodies ( see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96 ). Human monoclonal antibodies may be utilized and may be produced by using human hybridomas (see Cote, et al., 1983.
  • Antibodies are purified by well-known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Engineer, published by The Engineer, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28 ).
  • the CD47 antibodies of the invention are monoclonal antibodies.
  • Monoclonal antibodies that modulate, block, inhibit, reduce, antagonize, neutralize or otherwise interfere with CD47- and/or CD47/SIRP ⁇ -mediated cell signaling are generated, e.g., by immunizing an animal with membrane bound and/or soluble CD47, such as, for example, human CD47 or an immunogenic fragment, derivative or variant thereof.
  • the animal is immunized with cells transfected with a vector containing a nucleic acid molecule encoding CD47 such that CD47 is expressed and associated with the surface of the transfected cells.
  • the antibodies are obtained by screening a library that contains antibody or antigen binding domain sequences for binding to CD47.
  • This library is prepared, e.g., in bacteriophage as protein or peptide fusions to a bacteriophage coat protein that is expressed on the surface of assembled phage particles and the encoding DNA sequences contained within the phage particles (i.e., "phage displayed library”).
  • phage displayed library Hybridomas resulting from myeloma/B cell fusions are then screened for reactivity to CD47.
  • Monoclonal antibodies are prepared, for example, using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975 ).
  • a hybridoma method a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent.
  • the lymphocytes can be immunized in vitro.
  • the immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof.
  • peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired.
  • the lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell ( Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103 ).
  • Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin.
  • rat or mouse myeloma cell lines are employed.
  • the hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells.
  • a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells.
  • the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (“HAT medium”), which substances prevent the growth may HGPRT-deficient cells.
  • Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of monoclonal antibodies. ( See Kozbor, J. Immunol., 133:3001 (1984 ); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63 )).
  • the culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen.
  • the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunoabsorbent assay
  • the binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980 ).
  • the clones can be subcloned by limiting dilution procedures and grown by standard methods. ( See Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103 ).
  • Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium.
  • the hybridoma cells can be grown in vivo as ascites in a mammal.
  • the monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • Monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567 .
  • DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g . , by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).
  • the hybridoma cells serve as a preferred source of such DNA.
  • the DNA can be placed into expression vectors, which are then transfected into host cells such as Chinese hamster ovary (CHO) cells, Human Embryonic Kidney (HEK) 293 cells, simian COS cells, PER.C6®, NS0 cells, SP2/0, YB2/0, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
  • the DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences ( see U.S. Patent No.
  • non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.
  • Monoclonal antibodies of the invention include fully human antibodies or humanized antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin.
  • CD47 antibody is generated, for example, using the procedures described in the Examples provided below.
  • CD47 antibodies of the invention are identified using a modified RIMMS (Repetitive Immunization Multiple Sites) immunization strategy in mice and subsequent hybridoma generation.
  • RIMMS Repetitive Immunization Multiple Sites
  • a CD47 antibody is developed, for example, using phage-display methods using antibodies containing only human sequences. Such approaches are well-known in the art, e.g., in WO92/01047 and U.S. Pat. No. 6,521,404 . In this approach, a combinatorial library of phage carrying random pairs of light and heavy chains are screened using natural or recombinant source of cd47 or fragments thereof.
  • a CD47 antibody can be produced by a process wherein at least one step of the process includes immunizing a transgenic, non-human animal with human CD47 protein.
  • VH genes one or more VH genes, one or more D H genes, one or more J H genes, a mu constant region, and a second constant region (preferably a gamma constant region) are formed into a construct for insertion into an animal.
  • a second constant region preferably a gamma constant region
  • WO 92/03918 WO 92/22645 , WO 92/22647 , WO 92/22670 , WO 93/12227 , WO 94/00569 , WO 94/25585 , WO 96/14436 , WO 97/13852 , and WO 98/24884 and related family members.
  • HAMA Human anti-mouse antibody
  • HACA human anti-chimeric antibody
  • the production of antibodies with reduced immunogenicity is also accomplished via humanization, chimerization and display techniques using appropriate libraries.
  • murine antibodies or antibodies from other species can be humanized or primatized using techniques well known in the art. See e.g., Winter and Harris Immunol Today 14:43 46 (1993 ) and Wright et al. Crit, Reviews in Immunol. 12125-168 (1992 ).
  • the antibody of interest may be engineered by recombinant DNA techniques to substitute the CH1, CH2, CH3, hinge domains, and/or the framework domain with the corresponding human sequence ( See WO 92102190 and U.S. Patent Nos.
  • Ig cDNA for construction of chimeric immunoglobulin genes is known in the art ( Liu et al. P.N.A.S. 84:3439 (1987 ) and J. Immunol. 139:3521 (1987 )).
  • mRNA is isolated from a hybridoma or other cell producing the antibody and used to produce cDNA.
  • the cDNA of interest may be amplified by the polymerase chain reaction using specific primers ( U.S. Pat. Nos. 4,683,195 and 4,683,202 ).
  • a library is made and screened to isolate the sequence of interest.
  • the DNA sequence encoding the variable region of the antibody is then fused to human constant region sequences.
  • the sequences of human constant regions genes may be found in Kabat et al. (1991) Sequences of Proteins of immunological Interest, N.I.H. publication no. 91-3242 .
  • Human C region genes are readily available from known clones. The choice of isotype will be guided by the desired effecter functions, such as complement fixation, or activity in antibody-dependent cellular cytotoxicity. Preferred isotypes are IgG1, IgG2, IgG3, and IgG4. Either of the human light chain constant regions, kappa or lambda, may be used.
  • the chimeric, humanized antibody is then expressed by conventional methods.
  • Antibody fragments such as Fv, F(ab') 2 and Fab may be prepared by cleavage of the intact protein, e.g., by protease or chemical cleavage.
  • a truncated gene is designed.
  • a chimeric gene encoding a portion of the F(ab') 2 fragment would include DNA sequences encoding the CH1 domain and hinge region of the II chain, followed by a translational stop codon to yield the truncated molecule.
  • Consensus sequences of H and L J regions may be used to design oligonucleotides for use as primers to introduce useful restriction sites into the J region for subsequent linkage of V region segments to human C region segments.
  • C region cDNA can be modified by site directed mutagenesis to place a restriction site at the analogous position in the human sequence.
  • Expression vectors include plasmids, retroviruses, YACs, EBV derived episomes, and the like.
  • a convenient vector is one that encodes a functionally complete human CH or CL immunoglobulin sequence, with appropriate restriction sites engineered so that any VII or VL sequence can be easily inserted and expressed.
  • splicing usually occurs between the splice donor site in the inserted J region and the splice acceptor site preceding the human C region, and also at the splice regions that occur within the human CH exons. Polyadenylation and transcription termination occur at native chromosomal sites downstream of the coding regions.
  • the resulting chimeric antibody may be joined to any strong promoter, including retroviral LTRs, e.g., SV-40 early promoter, ( Okayama et al. Mol. Cell. Bio. 3:280 (1983 )), Rous sarcoma virus LTR ( Gorman et al. P.N.A.S. 79:6777 (1982 )), and moloney murine leukemia virus LTR ( Grosschedl et al. Cell 41:885 (1985 )).
  • retroviral LTRs e.g., SV-40 early promoter, ( Okayama et al. Mol. Cell. Bio. 3:280 (1983 )
  • Rous sarcoma virus LTR Gorman et al. P.N.A.S. 79:6777 (1982 )
  • moloney murine leukemia virus LTR Grosschedl et al. Cell 41:885 (1985 )
  • native Ig promoters and the like may be used.
  • human antibodies or antibodies from other species can be generated through display type technologies, including, without limitation, phage display, retroviral display, ribosomal display, and other techniques, using techniques well known in the art and the resulting molecules can be subjected to additional maturation, such as affinity maturation, as such techniques are well known in the art.
  • display type technologies including, without limitation, phage display, retroviral display, ribosomal display, and other techniques, using techniques well known in the art and the resulting molecules can be subjected to additional maturation, such as affinity maturation, as such techniques are well known in the art.
  • antibodies can be generated to CD47 expressing cells, soluble forms of CD47, epitopes or peptides thereof, and expression libraries thereto ( See e.g., U.S. Patent No. 5,703,057 ) which can thereafter be screened as described above for the activities described herein.
  • the CD47 antibodies of the invention can be expressed by a vector containing a DNA segment encoding the single chain antibody described above.
  • Vectors can include vectors, liposomes, naked DNA, adjuvant-assisted DNA, gene gun, catheters, etc.
  • Vectors include chemical conjugates such as described in WO 93/64701 , which has targeting moiety (e.g. a ligand to a cellular surface receptor), and a nucleic acid binding moiety (e.g. polylysine), viral vector (e.g. a DNA or RNA viral vector), fusion proteins such as described in PCT/US95/02140 ( WO 95/22618 ) which is a fusion protein containing a target moiety (e.g . an antibody specific for a target cell) and a nucleic acid binding moiety (e.g. a protamine), plasmids, phage, etc.
  • the vectors can be chromosomal, non-chromosomal or synthetic.
  • Retroviral vectors include moloney murine leukemia viruses. DNA viral vectors are preferred. These vectors include pox vectors such as orthopox or avipox vectors, herpesvirus vectors such as a herpes simplex I virus (HSV) vector (see Geller, A. I. et al., J. Neurochem, 64:487 (1995 ); Lim, F., et al., in DNA Cloning: Mammalian Systems, D. Glover, Ed. (Oxford Univ. Press, Oxford England) (1995 ); Geller, A. I. et al., Proc Natl. Acad. Sci.: U.S.A.
  • HSV herpes simplex I virus
  • Pox viral vectors introduce the gene into the cells cytoplasm.
  • Avipox virus vectors result in only a short term expression of the nucleic acid.
  • Adenovirus vectors, adeno-associated virus vectors and herpes simplex virus (IISV) vectors are preferred for introducing the nucleic acid into neural cells.
  • the adenovirus vector results in a shorter term expression (about 2 months) than adeno-associated virus (about 4 months), which in turn is shorter than HSV vectors.
  • the particular vector chosen will depend upon the target cell and the condition being treated.
  • the introduction can be by standard techniques, e.g. infection, transfection, transduction or transformation. Examples of modes of gene transfer include e.g ., naked DNA, CaPO 4 precipitation, DEAE dextran, electroporation, protoplast fusion, lipofection, cell microinjection, and viral vectors.
  • the vector can be employed to target essentially any desired target cell.
  • stereotaxic injection can be used to direct the vectors (e.g. adenovirus, IISV) to a desired location.
  • the particles can be delivered by intracerebroventricular (icv) infusion using a minipump infusion system, such as a SynchroMed Infusion System.
  • icv intracerebroventricular
  • a method based on bulk flow, termed convection has also proven effective at delivering large molecules to extended areas of the brain and may be useful in delivering the vector to the target cell.
  • convection A method based on bulk flow, termed convection, has also proven effective at delivering large molecules to extended areas of the brain and may be useful in delivering the vector to the target cell.
  • Other methods that can be used include catheters, intravenous, parenteral, intraperitoneal and subcutaneous injection, and oral or other known routes of administration.
  • vectors can be used to express large quantities of antibodies that can be used in a variety of ways. For example, to detect the presence of CD47 in a sample.
  • the antibody can also be used to try to bind to and disrupt CD47- and/or the CD47/SIRP ⁇ interaction and CD47/SIRP ⁇ -mediated signaling.
  • Techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein (see e.g., U.S. Patent No. 4,946,778 ).
  • methods can be adapted for the construction of Fab expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281 ) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof.
  • Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F(ab') 2 fragment produced by pepsin digestion of an antibody molecule; (ii) an Fab fragment generated by reducing the disulfide bridges of an F (ab')2 fragment; (iii) an Fab fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F v fragments.
  • the invention also includes F v , Fab, Fab' and F(ab') 2 CD47 fragments, single chain CD47 antibodies, single domain antibodies ( e.g. , nanobodies or VIIIIs), bispecific CD47 antibodies, and heteroconjugate CD47 antibodies.
  • Bispecific antibodies are antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for CD47.
  • the second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.
  • bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities ( Milstein and Cuello, Nature, 305:537-539 (1983 )). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993 , and in Traunecker et al., EMBO J., 10:3655-3659 (1991 ).
  • Antibody variable domains with the desired binding specificities can be fused to immunoglobulin constant domain sequences.
  • the fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions.
  • DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain are inserted into separate expression vectors, and are co-transfected into a suitable host organism.
  • the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture.
  • the preferred interface comprises at least a part of the CH3 region of an antibody constant domain.
  • one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g . tyrosine or tryptophan).
  • Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.
  • Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g . F(ab') 2 bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985 ) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab') 2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives.
  • TAB thionitrobenzoate
  • One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody.
  • the bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.
  • Fab' fragments can be directly recovered from E. coli and chemically coupled to form bispecific antibodies.
  • Shalaby et al., J. Exp. Med. 175:217-225 (1992 ) describe the production of a fully humanized bispecific antibody F(ab') 2 molecule.
  • Each Fab' fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody.
  • the bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.
  • bispecific antibodies have been produced using leucine zippers.
  • the leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion.
  • the antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers.
  • the fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V H and V L domains of one fragment are forced to pair with the complementary V L and V H domains of another fragment, thereby forming two antigen-binding sites.
  • V H and V L domains of one fragment are forced to pair with the complementary V L and V H domains of another fragment, thereby forming two antigen-binding sites.
  • sFv single-chain Fv
  • Antibodies with more than two valencies are contemplated.
  • trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991 ).
  • bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen disclosed herein.
  • an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc ⁇ R), such as Fc ⁇ RI (CD64), Fc ⁇ RII (CD32) and Fc ⁇ RIII (CD 16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen.
  • Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen.
  • antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA.
  • a cytotoxic agent or a radionuclide chelator such as EOTUBE, DPTA, DOTA, or TETA.
  • Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).
  • Heteroconjugate antibodies are also disclosed herein.
  • Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (see U.S. Patent No. 4,676,980 ), and for treatment of IIIV infection (see WO 91/00360 ; WO 92/200373 ; EP 03089 ).
  • the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents.
  • immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and melhyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980 .
  • an antibody of the invention can be modified with respect to effector function, so as to enhance, e.g ., the effectiveness of the antibody in treating diseases and disorders associated with aberrant CD47 signaling.
  • cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region.
  • the homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC).
  • ADCC antibody-dependent cellular cytotoxicity
  • an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities.
  • Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989 ) See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989 )).
  • the invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a toxin (e.g ., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).
  • a cytotoxic agent such as a toxin (e.g ., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).
  • Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.
  • a variety of radionuclides are available for the production of radioconjugated antibodies. Examples include 212 Bi, 131 I, 131 In, 90 Y, and 186 Re.
  • Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene).
  • SPDP N-succinimidyl-3-(
  • a ricin immunotoxin can be prepared as described in Vitetta et al., Science 238: 1098 (1987 ).
  • Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. ( See WO94/11026 ).
  • Coupling may be accomplished by any chemical reaction that will bind the two molecules so long as the antibody and the other moiety retain their respective activities.
  • This linkage can include many chemical mechanisms, for instance covalent binding, affinity binding, intercalation, coordinate binding and complexation.
  • the preferred binding is, however, covalent binding.
  • Covalent binding can be achieved either by direct condensation of existing side chains or by the incorporation of external bridging molecules.
  • Many bivalent or polyvalent linking agents are useful in coupling protein molecules, such as the antibodies of the present invention, to other molecules.
  • representative coupling agents can include organic compounds such as thioesters, carbodiimides, succinimide esters, diisocyanates, glutaraldehyde, diazobenzenes and hexamethylene diamines.
  • Preferred linkers are described in the literature. ( See , for example, Ramakrishnan, S. et al., Cancer Res. 44:201-208 (1984 ) describing use of MBS (M-maleimidobenzoyl-N-hydroxysuccinimide ester). See also, U.S. Patent No. 5,030,719 , describing use of halogenated acetyl hydrazide derivative coupled to an antibody by way of an oligopeptide linker.
  • MBS M-maleimidobenzoyl-N-hydroxysuccinimide ester
  • linkers include: (i) EDC (1-ethyl-3-(3-dimethylamino-propyl) carbodiimide hydrochloride; (ii) SMPT (4-succinimidyloxycarbonyl-alpha-methyl-alpha-(2-pridyl-dithio)-toluene (Pierce Chem. Co., Cat. (21558G); (iii) SPDP (succinimidyl-6 [3-(2-pyridyldithio) propionamido]hexanoate (Pierce Chem.
  • linkers described above contain components that have different attributes, thus leading to conjugates with differing physio-chemical properties.
  • sulfo-NHS esters of alkyl carboxylates are more stable than sulfo-NHS esters of aromatic carboxylates.
  • NHS-ester containing linkers are less soluble than sulfo-NHS esters.
  • the linker SMPT contains a sterically hindered disulfide bond, and can form conjugates with increased stability.
  • Disulfide linkages are in general, less stable than other linkages because the disulfide linkage is cleaved in vitro, resulting in less conjugate available.
  • Sulfo-NHS in particular, can enhance the stability of carbodimide couplings.
  • Carbodimide couplings (such as EDC) when used in conjunction with sulfo-NIIS, forms esters that are more resistant to hydrolysis than the carbodimide coupling reaction alone.
  • the antibodies disclosed herein can also be formulated as immunoliposomes.
  • Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985 ); Hwang et al., Proc. Natl Acad. Sci. USA, 77: 4030 (1980 ); and U.S. Pat. Nos. 4,485,045 and 4,544,545 .
  • Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556 .
  • Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter.
  • Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem., 257: 286-288 (1982 ) via a disulfide-interchange reaction.
  • formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LipofectinTM), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the foregoing mixtures may be appropriate in treatments and therapies in accordance with the present invention, provided that the active ingredient in the formulation is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the route of administration.
  • antibodies of the invention may be used as therapeutic agents.
  • Such agents will generally be employed to diagnose, prognose, monitor, treat, alleviate, and/or prevent a disease or pathology associated with aberrant CD47 expression, activity and/or signaling in a subject.
  • a therapeutic regimen is carried out by identifying a subject, e.g., a human patient suffering from (or at risk of developing) a disease or disorder associated with aberrant CD47 expression, activity and/or signaling, e.g ., a cancer or other neoplastic disorder, using standard methods.
  • An antibody preparation preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target.
  • Administration of the antibody may abrogate or inhibit or interfere with the expression, activity and/or signaling function of the target (e.g., CD47).
  • Administration of the antibody may abrogate or inhibit or interfere with the binding of the target (e.g., CD47) with an endogenous ligand (e.g., SIRP ⁇ ) to which it naturally binds.
  • the antibody binds to the target and modulates, blocks, inhibits, reduces, antagonizes, neutralizes, or otherwise interferes with CD47 expression, activity and/or signaling.
  • Hematological cancers include, e.g ., leukemia, lymphoma and myeloma.
  • leukemia include, by way of non-limiting example, acute lymphocytic leukemia (ALL); acute myeloid leukemia (AML); chronic lymphocytic leukemia (CLL); chronic myelogenous leukemia (CML); Myeloproliferative disorder/neoplasm (MPDS); and myclodysplasia syndrome.
  • ALL acute lymphocytic leukemia
  • AML acute myeloid leukemia
  • CLL chronic lymphocytic leukemia
  • CML chronic myelogenous leukemia
  • MPDS Myeloproliferative disorder/neoplasm
  • myclodysplasia syndrome myclodysplasia syndrome.
  • lymphoma include, by way of non-limiting example, Hodgkin's lymphoma, both indolent and aggressive non-Hodgkin's lymphoma, Burkitt's lymphoma, and follicular lymphoma (small cell and large cell).
  • Certain forms of myeloma include, by way of non-limiting example, multiple myeloma (MM), giant cell myeloma, heavy-chain myeloma, and light chain or Bence-Jones myeloma.
  • Solid tumors include, e.g., breast tumors, ovarian tumors, lung tumors, pancreatic tumors, prostate tumors, melanoma tumors, colorectal tumors, lung tumors, head and neck tumors, bladder tumors, esophageal tumors, liver tumors, and kidney tumors.
  • Symptoms associated with cancers and other neoplastic disorders include, for example, inflammation, fever, general malaise, fever, pain, often localized to the inflamed area, loss of appetite, weight loss, edema, headache, fatigue, rash, anemia, muscle weakness, muscle fatigue and abdominal symptoms such as, for example, abdominal pain, diarrhea or constipation.
  • a therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target.
  • the amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered.
  • Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 100 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.
  • Efficaciousness of treatment is determined in association with any known method for diagnosing or treating the particular inflammatory-related disorder. Alleviation of one or more symptoms of the inflammatory-related disorder indicates that the antibody confers a clinical benefit.
  • Methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme linked immunosorbent assay (ELISA) and other immunologically mediated techniques known within the art.
  • ELISA enzyme linked immunosorbent assay
  • antibodies directed against CD47 may be used in methods known within the art relating to the localization and/or quantitation of CD47 (e.g., for use in measuring levels of CD47 and/or both CD47 and SIRP ⁇ within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like).
  • antibodies specific to CD47, or derivative, fragment, analog or homolog thereof, that contain the antibody derived antigen binding domain are utilized as pharmacologically active compounds (referred to hereinafter as "Therapeutics").
  • an antibody specific for CD47 can be used to isolate a CD47 polypeptide, by standard techniques, such as immunoaffinity, chromatography or immunoprecipitation.
  • Antibodies directed against the CD47 protein (or a fragment thereof) can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling ( i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, or acetylcholinesterase;
  • suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin;
  • an example of a luminescent material includes luminol;
  • examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125 I, 131 I, 35 S or 3 H.
  • an antibody according to the invention can be used as an agent for detecting the presence of CD47 and/or both CD47 and SIRP ⁇ protein (or a protein fragment thereof) in a sample.
  • the antibody contains a detectable label.
  • Antibodies are polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof ( e.g., Fab, scFv, or F(ab') 2 ) is used.
  • labeling with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling ( i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled.
  • indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin.
  • biological sample is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.
  • the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo.
  • in vitro techniques for detection of an analyte mRNA include Northern hybridizations and in situ hybridizations.
  • in vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence.
  • In vitro techniques for detection of an analyte genomic DNA include Southern hybridizations.
  • ELISA Theory and Practice: Methods in Molecular Biology
  • Vol. 42 J. R. Crowther (Ed.) Human Press, Totowa, NJ, 1995
  • Immunoassay E. Diamandis and T. Christopoulus, Academic Press, Inc., San Diego, CA, 1996
  • Practice and Theory of Enzyme Immunoassays P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985 .
  • in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti-analyte protein antibody.
  • the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
  • the antibodies of the invention can be incorporated into pharmaceutical compositions suitable for administration.
  • Active compounds also referred to herein as "active compounds”
  • derivatives, fragments, analogs and homologs thereof can be incorporated into pharmaceutical compositions suitable for administration.
  • Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are provided, for example, in Remington's Pharmaceutical Sciences: The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa.: 1995 ; Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994 ; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York .
  • compositions typically comprise the antibody and a pharmaceutically acceptable carrier.
  • antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred.
  • peptide molecules can be designed that retain the ability to bind the target protein sequence.
  • Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. ( See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993 )).
  • the term "pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the fields. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, ringer's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated.
  • the formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.
  • a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration.
  • routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral ( e.g., inhalation), transdermal ( i.e., topical), transmucosal, and rectal administration.
  • Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
  • the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
  • a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
  • Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
  • the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
  • the compounds can also be prepared in the form of suppositories (e.g ., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
  • suppositories e.g ., with conventional suppository bases such as cocoa butter and other glycerides
  • retention enemas for rectal delivery.
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as sustained/controlled release formulations, including implants and microencapsulated delivery systems.
  • sustained/controlled release formulations including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • the active ingredients can be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules
  • sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides ( U.S. Pat. No.
  • copolymers of L-glutamic acid and y ethyl-L-glutamate non-degradable ethylene-vinyl acetate
  • degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOTTM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate)
  • poly-D-(-)-3-hydroxybulyric acid While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
  • Liposomal suspensions including liposomes targeted to infected cells with monoclonal antibodies to viral antigens
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • compositions can be included in a container, pack, or dispenser together with instructions for administration.
  • the formulation can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
  • the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent.
  • cytotoxic agent such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent.
  • Such molecules arc suitably present in combination in amounts that are effective for the purpose intended.
  • the active compounds are administered in combination therapy, i.e., combined with other agents, e.g., therapeutic agents, that are useful for treating pathological conditions or disorders, such as various forms of cancer, autoimmune disorders and inflammatory diseases.
  • agents e.g., therapeutic agents
  • the term "in combination” in this context means that the agents are given substantially contemporaneously, either simultaneously or sequentially. If given sequentially, at the onset of administration of the second compound, the first of the two compounds is preferably still detectable at effective concentrations at the site of treatment.
  • the combination therapy can include one or more antibodies of the invention coformulated with, and/or coadministered with, one or more additional therapeutic agents, e.g ., one or more cytokine and growth factor inhibitors, immunosuppressants, anti-inflammatory agents, metabolic inhibitors, enzyme inhibitors, and/or cytotoxic or cytostatic agents, as described in more detail below.
  • additional therapeutic agents e.g ., one or more cytokine and growth factor inhibitors, immunosuppressants, anti-inflammatory agents, metabolic inhibitors, enzyme inhibitors, and/or cytotoxic or cytostatic agents, as described in more detail below.
  • Such combination therapies may advantageously utilize lower dosages of the administered therapeutic agents, thus avoiding possible toxicities or complications associated with the various monotherapies.
  • Preferred therapeutic agents used in combination with an antibody of the invention are those agents that interfere at different stages in an inflammatory response.
  • one or more antibodies described herein may be coformulated with, and/or coadministered with, one or more additional agents such as other cytokine or growth factor antagonists (e.g ., soluble receptors, peptide inhibitors, small molecules, ligand fusions); or antibodies or antigen binding fragments thereof that bind to other targets (e.g., antibodies that bind to other cytokines or growth factors, their receptors, or other cell surface molecules); and anti-inflammatory cytokines or agonists thereof.
  • cytokine or growth factor antagonists e.g ., soluble receptors, peptide inhibitors, small molecules, ligand fusions
  • antibodies or antigen binding fragments thereof that bind to other targets (e.g., antibodies that bind to other cytokines or growth factors, their receptors, or other cell surface molecules); and anti-inflammatory cytokines or agonists thereof
  • the antibodies may be used as vaccine adjuvants against autoimmune disorders, inflammatory diseases, etc.
  • the combination of adjuvants for treatment of these types of disorders are suitable for use in combination with a wide variety of antigens from targeted self-antigens, i.e., autoantigens, involved in autoimmunity, e.g., myelin basic protein; inflammatory self-antigens, e.g., amyloid peptide protein, or transplant antigens, e.g ., alloantigens.
  • the antigen may comprise peptides or polypeptides derived from proteins, as well as fragments of any of the following: saccharides, proteins, polynucleotides or oligonucleotides, autoantigens, amyloid peptide protein, transplant antigens, allergens, or other macromolecular components. In some instances, more than one antigen is included in the antigenic composition.
  • Such modalities include, without limitation, advanced antibody therapeutics, such as bispecific antibodies, immunotoxins, and radiolabeled therapeutics, generation of peptide therapeutics, gene therapies, particularly intrabodies, antisense therapeutics, and small molecules.
  • bispecific antibodies can be generated that comprise (i) two antibodies- one with a specificity to CD47 and another to a second molecule that are conjugated together, (ii) a single antibody that has one chain specific to CD47 and a second chain specific to a second molecule, or (iii) a single chain antibody that has specificity to CD47 and a second molecule.
  • Such bispecific antibodies are generated using techniques that are well known for example, in connection with (i) and (ii) See e.g., Fanger et al. Immunol Methods 4:72-81 (1994 ) and Wright et al. Crit, Reviews in Immunol. 12125-168 (1992 ), and in connection with (iii) See e.g., Traunecker et al. Int. J. Cancer (Suppl.) 7:51-52 (1992 ).
  • antibodies can be modified to act as immunotoxins utilizing techniques that are well known in the art. See e.g., Vitetta Immunol Today 14:252 (1993 ). See also U.S. Patent No. 5,194,594 .
  • modified antibodies can also be readily prepared utilizing techniques that are well known in the art See e.g., Junghans et al. in Cancer Chemotherapy and Biotherapy 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996 )). See also U.S. Patent Nos.
  • therapeutic peptides can be generated that are directed against CD47.
  • Design and screening of peptide therapeutics is discussed in connection with Houghten et al. Biotechniques 13:412-421 (1992 ), Houghten PNAS USA 82:5131-5135 (1985 ), Pinalla et al. Biotechniques 13:901-905 (1992 ), Blake and Litzi-Davis BioConjugate Chem. 3:510-513 (1992 ).
  • Immunotoxins and radiolabeled molecules can also be prepared, and in a similar manner, in connection with peptidic moieties as discussed above in connection with antibodies.
  • CD47 molecule or a form, such as a splice variant or alternate form
  • gene and antisense therapeutics thereto through conventional techniques.
  • Such modalities can be utilized for modulating the function of CD47.
  • the antibodies of the present invention facilitate design and use of functional assays related thereto.
  • a design and strategy for antisense therapeutics is discussed in detail in International Patent Application No. WO 94/29444 . Design and strategies for gene therapy are well known.
  • screening assays for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) that modulate or otherwise interfere with the binding of CD47 to SIRP ⁇ , or candidate or test compounds or agents that modulate or otherwise interfere with the signaling function of CD47 and/or CD47-SIRP ⁇ .
  • modulators i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) that modulate or otherwise interfere with the binding of CD47 to SIRP ⁇ , or candidate or test compounds or agents that modulate or otherwise interfere with the signaling function of CD47 and/or CD47-SIRP ⁇ .
  • methods of identifying compounds useful to treat disorders associated with aberrant CD47 and/or CD47-SIRP ⁇ expression, activity and/or signaling can include those known or used in the art or those described herein.
  • CD47 can be immobilized on a microliter plate and incubated with a candidate or test compound, e.g ., a CD47 antibody, in the presence of SIRP ⁇ . Subsequently, bound SIRP ⁇ can be detected using a secondary antibody, and absorbance can be detected on a plate reader.
  • a candidate or test compound e.g ., a CD47 antibody
  • Methods of identifying compounds capable of promoting phagocytosis of tumor cells by macrophages are also provided. These methods can include those known or used in the art or those described herein.
  • macrophages are incubated with labeled tumor cells in the presence of a candidate compound, e.g ., a CD47 antibody. After a period of time, the macrophages can be observed for internalization of the tumor label to identify phagocytosis. Additional details regarding these methods, e.g., SIRP ⁇ blocking assays and phagocytosis assays, are provided in the Examples.
  • test compounds can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection.
  • biological libraries are limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. ( See, e.g., Lam, 1997. Anticancer Drug Design 12: 145 ).
  • a "small molecule” as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD.
  • Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules.
  • Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays disclosed herein.
  • a candidate compound may be introduced to an antibody-antigen complex and determining whether the candidate compound disrupts the antibody-antigen complex, wherein a disruption of this complex indicates that the candidate compound modulates the signaling function of CD47 and/or the interaction between CD47 and SIRP ⁇ .
  • a soluble CD47 and/or both CD47 and SIRP ⁇ protein is exposed to at least one neutralizing monoclonal antibody. Formation of an antibody-antigen complex is detected, and one or more candidate compounds are introduced to the complex. If the antibody-antigen complex is disrupted following introduction of the one or more candidate compounds, the candidate compounds is useful to treat disorders associated with aberrant CD47 and/or CD47-SIRP ⁇ signaling.
  • Determining the ability of the test compound to interfere with or disrupt the antibody-antigen complex can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the antigen or biologically-active portion thereof can be determined by detecting the labeled compound in a complex.
  • test compounds can be labeled with 125 I, 35 S, 14 C, or 3 H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting.
  • test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.
  • the assay comprises contacting an antibody-antigen complex with a test compound, and determining the ability of the test compound to interact with the antigen or otherwise disrupt the existing antibody-antigen complex.
  • determining the ability of the test compound to interact with the antigen and/or disrupt the antibody-antigen complex comprises determining the ability of the test compound to preferentially bind to the antigen or a biologically-active portion thereof, as compared to the antibody.
  • the assay comprises contacting an antibody-antigen complex with a test compound and determining the ability of the test compound to modulate the antibody-antigen complex. Determining the ability of the test compound to modulate the antibody-antigen complex can be accomplished, for example, by determining the ability of the antigen to bind to or interact with the antibody, in the presence of the test compound.
  • the antibody may be a neutralizing antibody, which modulates or otherwise interferes with CD47 activity and/or signaling.
  • the screening methods disclosed herein may be performed as a cell-based assay or as a cell-free assay.
  • the cell-free assays are amenable to use of either the soluble form or the membrane-bound form of CD47 and fragments thereof.
  • solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether) n , N-dodecyl--N,N-dimethyl-3-ammonio-l-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).
  • non-ionic detergents such as n-octylglucoside,
  • a fusion protein that adds a domain that allows one or both of the proteins to be bound to a matrix can be provided.
  • GST-antibody fusion proteins or GST-antigen fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St.
  • the test compound is then combined with the test compound, and the mixture is incubated under conditions conducive to complex formation (e.g ., at physiological conditions for salt and pII). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly. Alternatively, the complexes can be dissociated from the matrix, and the level of antibody-antigen complex formation can be determined using standard techniques.
  • immobilizing proteins on matrices can also be used in the screening assays
  • the antibody e.g., the 2 ⁇ 1 antibody, or an antibody having a variable heavy chain selected from SEQ ID NOs: 5-30 and a variable light chain selected from SEQ ID NOs: 31-4
  • the antigen e.g. CD47 protein
  • Biotinylated antibody or antigen molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (e.g ., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical).
  • biotinylation kit Pierce Chemicals, Rockford, Ill.
  • other antibodies reactive with the antibody or antigen of interest but which do not interfere with the formation of the antibody-antigen complex of interest, can be derivatized to the wells of the plate, and unbound antibody or antigen trapped in the wells by antibody conjugation.
  • Methods for detecting such complexes include immunodetection of complexes using such other antibodies reactive with the antibody or antigen.
  • Novel agents may be identified by any of the aforementioned screening assays and may be used for treatments as described herein.
  • the CD47 MAbs of the invention are used in diagnostic and prophylactic formulations.
  • a CD47 MAb of the invention is administered to patients that are at risk of developing one or more of the aforementioned diseases, such as for example, without limitation, cancer or other neoplastic condition.
  • a patient's or organ's predisposition to one or more of the aforementioned cancers or other neoplastic conditions can be determined using genotypic, serological or biochemical markers.
  • the CD47 antibody is administered to human individuals diagnosed with a clinical indication associated with one or more of the aforementioned diseases, such as for example, without limitation, cancer or other neoplastic condition. Upon diagnosis, the CD47 antibody is administered to mitigate or reverse the effects of the clinical indication associated with one or more of the aforementioned diseases.
  • Antibodies of the invention are also useful in the detection of CD47 and/or SIRP ⁇ in patient samples and accordingly are useful as diagnostics.
  • the CD47 antibodies of the invention are used in in vitro assays, e.g., ELISA, to detect CD47 and/or SIRP ⁇ levels in a patient sample.
  • a CD47 antibody of the invention is immobilized on a solid support (e.g., the well(s) of a microliter plate).
  • the immobilized antibody serves as a capture antibody for any CD47 and/or SIRP ⁇ that may be present in a test sample.
  • the solid support Prior to contacting the immobilized antibody with a patient sample, the solid support is rinsed and treated with a blocking agent such as milk protein or albumin to prevent nonspecific adsorption of the analyte.
  • the wells are treated with a test sample suspected of containing the antigen, or with a solution containing a standard amount of the antigen.
  • a test sample suspected of containing the antigen
  • a solution containing a standard amount of the antigen is, e.g., a scrum sample from a subject suspected of having levels of circulating antigen considered to be diagnostic of a pathology.
  • the solid support is treated with a second antibody that is detectably labeled.
  • the labeled second antibody serves as a detecting antibody.
  • the level of detectable label is measured, and the concentration of CD47 and/or SIRP ⁇ in the test sample is determined by comparison with a standard curve developed from the standard samples.
  • a disease e.g., a clinical indication associated with ischemia, an autoimmune or inflammatory disorder
  • samples of blood are taken from subjects diagnosed as being at various stages in the progression of the disease, and/or at various points in the therapeutic treatment of the disease.
  • a range of concentrations of the antigen that may be considered characteristic of each stage is designated.
  • CD47 antibodies were generated by immunizing mice with a recombinant protein representing CD47-IgV (immunoglobin-like variable-type), implementing a modified rapid immunization strategy in multiple sites ( Kilpatrick et al. (1997) Rapid development of affinity matured monoclonal antibodies using RIMMS. Hybridoma 16, 381-389 ).
  • half of the mice in the immunized group received a single injection of the anti-mouse GITR agonist antibody, DTA-1.
  • lymph nodes from all mice were harvested and dissociated, thereby enabling B-cell isolation and subsequent fusion to a mouse myeloma cell line.
  • Hybridoma supernatants were screened for binding to CD47 by ELISA and by flow cytometry on Daudi (ATCC# CCL-213) cells ( Figure 1A ). Hybridoma supernatants were also analyzed for the ability to block the CD47-SIRP ⁇ interaction ( Figure 1B ).
  • Recombinant CD47 was immobilized on a Medisorp (NUNC) microtiter plate and subsequently incubated with the hybridoma supernatants in the presence of recombinant human SIRP ⁇ -ECD fused to a human IgG Fc domain. Bound SIRP ⁇ was detected using an HRP conjugated anti-human IgG Fc specific secondary antibody (Jackson Immuno Research), and absorbance at 650nm detected in plate reader.
  • Exemplary murine CD47 antibodies of the present invention are shown in Figure 2 .
  • Affinity ranking of SIRP ⁇ blocking CD47 antibodies was conducted by flow cytometry on Raji (ATCC# CCL-86) ( Figure 2A ) and CCRF-CEM (ATCC# CCL-119) cells ( Figure 2B ).
  • Bound CD47 antibodies were detected using a FITC conjugated anti-mouse IgG secondary antibody (Jackson ImmunoResearch).
  • the CD47 antibody known in the art, B6II12 was included as a positive control (See, e.g., U.S. Patent 5,057,604 ).
  • the antibodies of the present invention display higher affinity toward the endogenous (cell surface) form of CD47 compared to the B6H12 and 2D3 antibodies.
  • the potency of SIRP ⁇ blocking by CD47 antibodies was measured by an ELISA wherein recombinant His-tagged-CD47-IgV was immobilized on a Medisorp microtiter plate. Binding of recombinant SIRP ⁇ fused to an Fc domain of human IgG was monitored in the presence of increasing amounts of the CD47 antibodies. Bound SIRP ⁇ was determined using an HRP conjugated anti-human IgG (Fc specific) secondary antibody (Jackson ImmunoResearch). The antibodies of the present invention display enhanced potency of SIRP ⁇ blocking compared to the B6H 12 antibody.
  • Figure 3A shows representative data of the ELISA based SIRP ⁇ blocking assay.
  • CD47 antibodies were analyzed by flow cytometry for their ability to block recombinant SIRP ⁇ binding to cell surface CD47.
  • CCRF-CEM ATCC# CCL-119 cells were used as the source of CD47 in the assay and binding of recombinant SIRP ⁇ fused to an Fc domain of human IgG was monitored in the presence of increasing amounts of the CD47 antibodies.
  • Bound SIRP ⁇ was determined using an APC conjugated anti-human IgG (Fc specific) secondary antibody (Jackson ImmunoResearch) ( Figure 3B ).
  • B6II12 and commercially available non-SIRP ⁇ blocking CD47 antibody 2D3 where used a positive and negative controls respectively.
  • SIRP ⁇ blocking CD47 antibodies were analyzed for their ability to induce cellular clustering, as known as homotypic interactions, between CD47 positive cells. Daudi and Raji cells were used as candidate CD47 expressing cells lines. Among the antibodies examined, the 2A1 antibody of the present invention was the only SIRP ⁇ blocking antibody that did not promote homotypic interactions of CD47 expressing cells.
  • CD47 antibodies were screened for RBC agglutination, as observed by the ability of an antibody to prevent the settling of human RBCs. Unexpectedly, the 2A1 antibody was found to be unique among other CD47 antibodies for its inability to promote hemagglutination, while having high affinity and the ability to block SIRP ⁇ . Other antibodies that displayed reduced hemagglutination did not block SIRP ⁇ binding to CD47.
  • hemagglutinating capacity of CD47 antibodies human RBCs were diluted to 10% in PBS and incubated at 37°C for 2-6 hours with a titration of CD47 antibodies in a round bottom 96 well plate.
  • Evidence of hemagglutination is demonstrated by the presence of non-settled RBCs, appearing as a haze compared to a punctuate red dot of non-hemagglutinated RBCs.
  • CD47 antibodies of the invention particularly the antibody referred to herein as 2A1 did not exhibit hemagglutinating activity.
  • the graph shows the quantitation of the hemagglutination assay, denoted "hemagglutination index" determined by quantitating the area of the RBC pellet in the presence of the antibody, normalized to that in the absence of the antibody.
  • the murine 9E4 antibody caused the most profound hemagglutination at all concentrations tested.
  • the 9E4 antibody binds CD47 and blocks CD47 interaction with SIRP ⁇ ; however, the 9E4 antibody causes profound hemagglutination.
  • the VH chain region of the 9E4 antibody is provided below.
  • the VL chain region of the 9E4 antibody is provided below.
  • control antibody B6H12 caused hemagglutination as is expected for SIRP ⁇ blocking CD47 antibodies.
  • Figure 4C shows the results of screening additional CD47 antibodies in the RBC hemagglutination assay.
  • the commercially available CD47 monoclonal antibody 2D3, which does not block SIRP ⁇ did not cause hemagglutination.
  • other commercially available CD47 antibodies e.g ., CC2C6, BRIC126, and B6H12
  • FIG 4C shows that prior to the invention described herein, existing antibodies that blocked SIRP ⁇ caused hemagglutination, while existing antibodies, such as 2D3, that did not block SIRP ⁇ did not cause hemagglutination.
  • the antibodies of the invention e.g., the 2A1 antibody and its humanized derivatives
  • the murine 1134 antibody displayed a narrow range of hemagglutination.
  • the VH chain region of the 1B4 antibody is provided below.
  • the VL chain region of the 1B4 antibody is provided below.
  • the hemagglutinating capacity of humanized antibodies derived from the murine 2A1 was tested as above.
  • the representative humanized antibody AB6.12 in numerous human IgG isotypes did not cause any RBC hemagglutination.
  • 2A1 and 2A1-xi were included as controls for non-hemagglutinating antibodies, whereas B6II12 and 9E4 were included as positive controls for hemagglutination ( Figure 4F ).
  • the ability of murine 2A1 to bind to cynomolgus (cyno) monkey CD47 was assessed.
  • the B6H12 antibody has previously been reported to be cross-reactive with cyno CD47 and was used as a positive control for the presence on cyno CD47 in the assay.
  • the experiment to measure binding of 2A1 to cynomolgus monkey CD47 was designed to compare binding of 2A1 to CD47 on cynomolgus monkey B-cells and human cells, wherein the Raji cell line was used as a human CD47 positive cell.
  • Cynomolgus peripheral blood mononuclear cells were isolated from cynomolgus whole blood by ficoll-paque gradient centrifugation. Cynomolgus and human B-cells (Raji) were labeled with the human CD20 antibody ofatumumab (Arzerra) at 10 ⁇ g/ml, and reacted with a dilution series of murine CD47 antibody 2A1 or B6H12. B-cells labeled with human CD20 antibody were detected with polyclonal anti-human antibody conjugated to DyLite 649, while the CD47 murine antibodies were detected with polyclonal anti-mouse antibody conjugated to DyLite 488.
  • RNA ribonucleic acid
  • RT-PCR reverse transcription polymerase chain reaction
  • the forward primers (murine IgG leader) are provided below.
  • Name Sequence VH1-1 CACTGCAGGTRTCCACTCC (SEQ ID NO: 82) VH1-2 CATAGCAGGTGTCCACTCC (SEQ ID NO: 83) VH1-3 CRCTACAGGTGTCCACTCC (SEQ ID NO: 84) VH1-4 GCYACAGMTGTCCACTCC (SEQ ID NO: 85) VH1-5 CACTGCAGGTGTCCWMTCC (SEQ ID NO: 86) VH1-6 CRCTRCAGGTGTKCACTCC (SEQ ID NO: 87) VH1-7 GCTAWMGGTGTCCACTCC (SEQ ID NO: 88) VH1-8 CCTCAGGTGTCCACTCC (SEQ ID NO: 89) VH1-9 GCTACAGGTGCTCACTCC (SEQ ID NO: 90) VH1-10 CACTGCAGGTGTCCTCTCT (SEQ ID NO: 91) VH1-11 CAYTGCAGGTGTCCAYTGC
  • the reverse primer (murine IgG constant) is provided below.
  • the forward primers (murine IgKappa leader) are provided below.
  • Name Sequence VK1-1 CTGWTGTTCTGGATTCCTG (SEQ ID NO: 115) VK1-2 GGTCAGACAGTCAGCAGT (SEQ ID NO: 116) VK2 GTGCTCTGGATTCGGGAA (SEQ ID NO: 117) VK4/5-1 CAGCTTCYTGCTAATCAGTG (SEQ ID NO: 118) VK4/5-2 CTAATCAGTGCTTCAGGA (SEQ ID NO: 119) VK8-1 GTGGGTATCTGGTRCSTGTG (SEQ ID NO: 120) VK8-2 GGAAATTTAAAAGTACCTGTGGG (SEQ ID NO: 121) VK9A/9B-1 GGTTTCMAGGTRCCAGATGT (SEQ ID NO: 122) VK9A/9B-2 CTCTGGTTYCCAGGTATC (SEQ ID NO: 123) VK10 CTGTTTTCAAGGTRCCAGATGT (SEQ ID NO: 12
  • the reverse primer (murine IgKappa constant) is provided below.
  • Name Sequence LC -rev GCGTCTAGAACTGGATGGTGGGAAGATGG (SEQ ID NO: 146)
  • VH and VL were subsequently cloned in-frame into vectors containing appropriate antibody secretion sequences and human IgG1 and Igkappa constants regions, respectively, to generate murine:human chimeric DNA constructs. These constructs were co-transfected into 293Freestyle cells (Life Technologies) and the resultant antibody was purified from the cell culture supernatant by Protein-A chromatography. To determine that the correct VH and VL sequences had been identified, the chimeric 2A1 (denoted 2A1-xi) was compared to the murine parental 2A1 antibody and CD47 binding assay by How cytometry on Raji cells ( Figure 6 ). B6H12 was also included as a positive control in this assay.
  • Bound 2A1-xi was detected using a FITC-conjugated anti-human IgG secondary antibody.
  • Bound 2A1 and B6II12 were detected using a FITC-conjugated anti-mouse IgG secondary antibody.
  • Apparent affinities were determined by non-linear fits (Prism Graphpad Software) of the median fluorescence intensities at various antibody concentrations (Table 2).
  • the 2A1-xi antibody has a similar binding affinity as the murine 2A1 antibody toward cell surface CD47, demonstrating that the VH and VL sequences had been properly identified.
  • the murine 2A1 CD47 antibody was humanized to reduce the potential of immunogenicity when administered to human patient.
  • the sequences of the VH and VL region of 2A1 were compared to human antibody sequences in the IMGT databank.
  • a structural model was generated of the 2A1 VII and VL regions using the known structures of the most closely related humanized and human antibodies in the Protein Data Bank (PDB).
  • the 3 complementary determining regions (CDR) in both the heavy and light chains of the 2A1 antibody were fixed and the murine frameworks were replaced with numerous human frameworks that had the highest possibility of maintaining the proper orientation of the CDRs.
  • Constructs corresponding to each the humanized 2A1 variants were generated by gene synthesis and cloned in frame into vectors containing an appropriate secretion sequence and human IgG1 and Igkappa constant regions.
  • Various combinations of humanized heavy and light chains were co-transfected in to 293Freestyle cells (Life Technologies), and resultant antibodies were purified from the cell culture supernatant by Protein-A chromatography.
  • Humanized antibodies were tested for their ability to bind Raji cells by flow cytometry ( Figure 7 ).
  • the 2A1-xi antibody was used as a control in most of these assays to set the benchmark for binding affinity.
  • Humanized antibodies were further optimized to enhance expression and reduce problematic sites including potential isomerization and deamidation sites.
  • An example of an optimized humanized antibody derived from the murine 2A1 antibody is denoted as AB6.12 antibody, which displays very similar binding affinity as the 2A1-xi antibody ( Figure 7H ; Table 3).
  • Apparent affinities were determined by non-linear fits (Prism Graphpad Software) of the median fluorescence intensities at various antibody concentrations.
  • the AB6.12 antibody was subsequently converted from an IgG1 to other human IgG isotypes by replacing the constant domain of the heavy chain.
  • changing the IgG isotype to a hinge stabilized version of IgG4 IgG4P: S228P
  • reduced Fc receptor binding variant of the hinge stabilized IgG4 IgG4PE: S228P/L235E
  • Apparent affinities were determined by non-linear fits (Prism Graphpad Software) of the median fluorescence intensities at various antibody concentrations. Table 4.
  • CD47 antibodies were tested to ensure the SIRP ⁇ blocking functionality was intact.
  • multiple IgG isotypes of the humanized antibody, AB6.12 blocked the SIRP ⁇ :CD47 interaction, using the How cytometry-based method described above in Example 3.
  • Exemplary CD47 antibodies and their corresponding VII region and VL region include those provided in Table 1.
  • an amino acid sequence motif, "NA,” at the beginning of VH CDR3 (SEQ ID NO: 52 or SEQ ID NO: 77) is important for binding of the CD47 antibodies described herein.
  • the CD47 antibodies of the invention do not bind to their target or bind to their target with lower affinity than they would in the presence of amino acid residues "NA.” For example, when the "NA" motif was changed to more canonical motifs of "AR” or "AT,” binding was substantially reduced (i.e., greater than ten-fold).
  • the CD47 antibodies of the invention bind to their target with equivalent affinity compared to binding in the presence of amino acid residues "NA.”
  • FIG. 8A An image of the trace from size exclusion chromatography using an AKTA FLPC with a superdex200 column is shown in Figure 8A .
  • the IgG1, IgG4P, and IgG4PE variants of the AB6.12 antibody are shown. All three variant are over 98% monomeric.
  • Figure 8B is a photograph of a coomassie blue stained SDS-PAGE gel of numerous humanized variants of 2A1 under reducing (R) and non-reducing (NR) conditions.
  • CD47 is a cell surface receptor that is upregulated on tumor cells and is also thought to contribute to immune evasion through its interaction with its natural ligand SIRP ⁇ . Ligation of CD47 to SIRP ⁇ on macrophages results in decreased phagocytic activity. As described in detail below, it was determined if the CD47 binding and SIRP ⁇ blocking activity of the 2A1 antibody, and variations thereof, promote tumor cell phagocytosis in the presence of human macrophages.
  • PBMCs peripheral blood cells
  • monocytes monocyte derived macrophages
  • AIM-V media AIM-V media
  • MDMs monocyte derived macrophages
  • CCRF-CFM The human tumor cell line CCRF-CFM was chosen as a target cell type because of its high CD47 expression.
  • CCRF-CEM cells were labeled with 0.3 ⁇ M CFSE at 37°C for 15 minutes, then washed and added to MDMs at a ratio of 4:1 tumor cells per phagocyte, and CD47 antibody was added at various concentrations.
  • Phagocytosis of target cells was allowed for 3 hours. Subsequently, non-phagocytosed target cells were washed away with PBS. The remaining phagocytes were scraped off, stained with an antibody to the macrophage marker CD 14 conjugated to DyLite 649 (Biolegend), and analyzed by flow cytometry. Phagocytosis was measured by gating on live cells that were FL4 positive (CD14+), and then assessing the percent of FL1 (CFSE+) positive cells.
  • Figure 9 shows that the CD47 antibody 2A1 and its humanized variants demonstrated a dose-dependent increase in phagocytosis of tumor cells by MDMs.
  • Antibody 2A1 and the humanized variant A132.05 were unique in their ability to induce phagocytosis of tumor cells at 66.7 pM, whereas B6II12 had no activity at that concentration ( Figure 9A ).
  • Figure 9B shows how 2A1, and the humanized variants AB2.05, AB6.12-IgG1, AB6.12-IgG4P, and AB6.12-IgG4PE all induce maximal phagocytosis at 0.3 ⁇ g/ml or 2 nM, while B6H12 requires higher concentrations.
  • CD47 antibody 2A1 (and humanized variants derived from it), induce macrophage-mediated phagocytosis of CD47 positive tumor cells.
  • CCFR-CEM cells were utilized as the CD47 positive target cell.
  • the anti-tumor activity of the murine CD47 antibodies was evaluated in a Raji model of lymphoma.
  • Raji cells were implanted subcutaneously in NOD/SCID mice, and randomized into 5 groups (10 mice per group, day 0).
  • Group 1 Vehicle (buffer only);
  • Group 2 B6H12 (positive control);
  • Group 3 1B4;
  • Group 4 2A1;
  • Group 5 9E4.
  • Treatment with each antibody or vehicle (buffer only) began when tumors were palpable (50 mm 3 , day 13) and mice were euthanized when their tumor volumes reached ⁇ 1500 mm 3 . Tumor volumes were measured 3 times per week.
  • Antibodies were dosed intravenously (IV) with 200 ⁇ g 3 times per week for 3 weeks (9 total doses per mouse). Treatment started on day 13 and ended on day 32.
  • CD47 antibodies of the invention demonstrated anti-tumor activity in this animal model of lymphoma.
  • Group 1 vehicle only
  • Group 2 B6H 12.2
  • Group 3 (1B4)
  • Group 4 (2A1) required ⁇ 85 days
  • Group 5 (9E4) required ⁇ 40 days to reach a tumor volume ⁇ 1500 mm 3 .
  • B6II12 that was known to bind CD47, block CD47 interaction with SIRP ⁇ , and suppress tumor formation in mouse models of human cancer.
  • tumor suppression activity of these CD47 antibodies did not correlate with their potency of binding CD47 or blocking CD47 interaction with SIRP ⁇ , which would be expected based upon published data.
  • 2A1, 1B4, and 9E4 had similar affinity for CD47 and similar potency for blocking CD47 interaction with SIRP ⁇ .
  • the enhanced efficacy of 2A1 cannot be explained by differences in the Fc domain of the antibodies described since all antibodies used in this study were comprised of identical mouse IgGI domains.
  • the 2A1 antibody possesses unexpected and unique characteristics including the inability to induce homotypic interactions between CD47 expressing cells, e.g., red blood cells, and enhanced tumor suppression activity that cannot be explained by enhanced binding to CD47 or an enhanced ability to block CD47 interaction with SIRP ⁇ .
  • AB6.12 was constructed (as described in EXAMPLE 8) into human IgG1 (Group 3), human IgG4P (Group 4) and human IgG4PE (Group 4).
  • this experiment was designed to address the influence of 2A1 humanization on its tumor suppression activity and the potential role of Fc domain effector function that is known in the art to contribute to the antitumor activities of many antibodies.
  • human IgG1 possesses significantly more effector function compared to human IgG4P.
  • IgG4PE was developed to further reduce effector function.
  • humanization of 2A1 did not diminish the antitumor activity of 2A1, and in fact may have enhanced it.
  • AB6.12-hIgG1, AB6.12-hIgG4P, and AB6.12-hIgG4PH all showed similar anti-tumor activity that appears significantly greater than mouse 2A1 (2A1 mIgG).
  • This result is unexpected since 2A1mIgG1, AB6.12-hIgG1, AB6.12-hIgG4P and AB6.12-hIgG4PE have similar CD47 binding and SIRP ⁇ blocking activities.
  • AB6.12-hIgG1, AB6.12-hIgG4P and AB6.l2-hIgG4PE have similar anti-tumor activities, it appears that effector function does play a role in the efficacy of the humanized 2A1 antibody AB6.12.
  • CD47 is 5 pass transmembrane protein with a single extracellular IgV (immunoglobin-like variable-type) domain that is highly glycosylated at 6 sites.
  • the structure of the CD47-IgV domain has been solved in complex with the IgV domain of SIRP ⁇ , its natural ligand (Protein Data Bank (PDB) Reference No. 2JJS; Hatherley et al., 2008 Mol Cell, 25;31(2): 266-77 ( Figure 11A )).
  • PDB Protein Data Bank
  • the structure shows SIRP ⁇ -IgV binding to CD47-IgV on an apical epitope including the N-terminal pyroglutamate of CD47.
  • the 2A1 epitope on CD47 is discontinuous, and includes residues Y37, K39, K41, the KGRD (SEQ ID NO: 56) loop (residues 43-46), D51, H90, N93, E97, T99, E104, and F106 of CD47 when numbered in accordance with SEQ ID NO: 147 ( i.e., SEQ ID NO: 48 excluding the signal sequence (amino acids 1-18)).
  • SEQ ID NO: 48 i.e., SEQ ID NO: 48 excluding the signal sequence (amino acids 1-18)
  • the structure of 2A1 bound to CD47 also reveals that the VII is primarily involved in binding to the KGRD (SEQ ID NO: 56) loop of CD47, while the VK domain interacts with apical residues including Y37, T102, and E104, which are involved in SIRP ⁇ binding.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (12)

  1. Isolierter monoklonaler Antikörper oder immunologisch aktives Fragment davon, der/das an menschliches CD47 bindet, wobei der Antikörper oder das immunologisch aktive Fragment davon an ein diskontinuierliches Epitop am CD47 bindet, wobei das diskontinuierliche Epitop Aminosäurereste Y37, K39, K41, K43, G44, R45, D46, D51, H90, N93, E97, T99, E104 und E106 von CD47 umfasst, wenn sie gemäß SEQ ID Nr.: 147 nummeriert sind, und wobei der Antikörper oder das immunologisch aktive Fragment davon CD47 daran hindert, mit dem Signal-Regulatory-Protein α (SIRPα) zu interagieren, und kein signifikantes Maß an Agglutination von Zellen nach der Verabreichung bewirkt.
  2. Antikörper oder immunologisch aktives Fragment davon nach Anspruch 1, wobei der Antikörper oder das immunologisch aktive Fragment davon chimärisch oder humanisiert ist.
  3. Antikörper oder immunologisch aktives Fragment davon nach Anspruch 1 oder 2, wobei der Antikörper oder das immunologisch aktive Fragment davon die durch Makrophagen herbeigeführte Phagozytose einer CD47-exprimierenden Zelle fördert.
  4. Antikörper oder immunologisch aktives Fragment davon nach einem der Ansprüche 1 bis 3, wobei der Antikörper oder das immunologisch aktive Fragment davon ein IgG-Isotyp ist, ausgewählt aus der Gruppe bestehend aus Isotyp IgG 1, Isotyp IgG2, Isotyp IgG3 und Isotyp IgG4.
  5. Antikörper oder immunologisch aktives Fragment davon nach einem der Ansprüche 1 bis 3, wobei der Antikörper oder das immunologisch aktive Fragment davon ein IgG-Isotyp ist, ausgewählt aus IgG4P und IgG4PE.
  6. Antikörper oder immunologisch aktives Fragment davon nach einem der Ansprüche 1 bis 5, wobei der Antikörper oder das immunologisch aktive Fragment davon umfasst:
    (i) eine VH-CDR1-Sequenz gemäß SEQ ID Nr.: 50,
    eine VH-CDR2-Sequenz gemäß SEQ ID Nr.: 72,
    eine VH-CDR3-Sequenz gemäß SEQ ID Nr.: 52,
    eine VL-CDR1-Sequenz gemäß SEQ ID Nr.: 53,
    eine VL-CDR2-Sequenz gemäß SEQ ID Nr.: 71, und
    eine VL-CDR3-Sequenz gemäß SEQ ID Nr.: 55;
    (ii) eine VH-CDR1-Sequenz gemäß SEQ ID Nr.: 50,
    eine VH-CDR2-Sequenz gemäß SEQ ID Nr.: 51,
    eine VH-CDR3-Sequenz gemäß SEQ ID Nr.: 52,
    eine VL-CDR1-Sequenz gemäß SEQ ID Nr.: 53,
    eine VL-CDR2-Sequenz gemäß SEQ ID Nr.: 54, und
    eine VL-CDR3-Sequenz gemäß SEQ ID Nr.: 55;
    (iii) eine VH-CDR1-Sequenz gemäß SEQ ID Nr.: 50,
    eine VH-CDR2-Sequenz gemäß SEQ ID Nr.: 51,
    eine VH-CDR3-Sequenz gemäß SEQ ID Nr.: 52,
    eine VL-CDR1-Sequenz gemäß SEQ ID Nr.: 67,
    eine VL-CDR2-Sequenz gemäß SEQ ID Nr.: 69, und
    eine VL-CDR3-Sequenz gemäß SEQ ID Nr.: 55;
    (iv) eine VH-CDR1-Sequenz gemäß SEQ ID Nr.: 50,
    eine VH-CDR2-Sequenz gemäß SEQ ID Nr.: 51,
    eine VH-CDR3-Sequenz gemäß SEQ ID Nr.: 52,
    eine VL-CDR1-Sequenz gemäß SEQ 1D Nr.: 67,
    eine VL-CDR2-Sequenz gemäß SEQ 1D Nr.: 70, und
    eine VL-CDR3-Sequenz gemäß SEQ 1D Nr.: 55;
    (v) eine VH-CDR1-Sequenz gemäß SEQ ID Nr.: 50,
    eine VH-CDR2-Sequenz gemäß SEQ ID Nr.: 51,
    eine VH-CDR3-Sequenz gemäß SEQ ID Nr.: 52,
    eine VL-CDR1-Sequenz gemäß SEQ ID Nr.: 68,
    eine VL-CDR2-Sequenz gemäß SEQ ID Nr.: 54, und
    eine VL-CDR3-Sequenz gemäß SEQ ID Nr.: 55;
    (vi) eine VH-CDR1-Sequenz gemäß SEQ ID Nr.: 50,
    eine VH-CDR2-Sequenz gemäß SEQ ID Nr.: 72,
    eine VH-CDR3-Sequenz gemäß SEQ ID Nr.: 52,
    eine VL-CDR1-Sequenz gemäß SEQ ID Nr.: 68,
    eine VL-CDR2-Sequenz gemäß SEQ ID Nr.: 54, und
    eine VL-CDR3-Sequenz gemäß SEQ ID Nr.: 55;
    (vii) eine VH-CDR1-Sequenz gemäß SEQ ID Nr.: 50,
    eine VH-CDR2-Sequenz gemäß SEQ ID Nr.: 72,
    eine VH-CDR3-Sequenz gemäß SEQ ID Nr.: 52,
    eine VL-CDR1-Sequenz gemäß SEQ ID Nr.: 68,
    eine VL-CDR2-Sequenz gemäß SEQ ID Nr.: 71, und
    eine VL-CDR3-Sequenz gemäß SEQ ID Nr.: 55;
    (viii) eine VH-CDR1-Sequenz gemäß SEQ ID Nr.: 50,
    eine VH-CDR2-Sequenz gemäß SEQ ID Nr.: 76,
    eine VH-CDR3-Sequenz gemäß SEQ ID Nr.: 52,
    eine VL-CDR1-Sequenz gemäß SEQ ID Nr.: 68,
    eine VL-CDR2-Sequenz gemäß SEQ ID Nr.: 54, und
    eine VL-CDR3-Sequenz gemäß SEQ ID Nr.: 55;
    (ix) eine VH-CDR1-Sequenz gemäß SEQ ID Nr.: 50,
    eine VH-CDR2-Sequenz gemäß SEQ ID Nr.: 76,
    eine VH-CDR3-Sequenz gemäß SEQ ID Nr.: 52,
    eine VL-CDR1-Sequenz gemäß SEQ ID Nr.: 68,
    eine VL-CDR2-Sequenz gemäß SEQ ID Nr.: 71, und
    eine VL-CDR3-Sequenz gemäß SEQ ID Nr.: 55;
    (x) eine VH-CDR1-Sequenz gemäß SEQ ID Nr.: 50,
    eine VH-CDR2-Sequenz gemäß SEQ ID Nr.: 51,
    eine VH-CDR3-Sequenz gemäß SEQ ID Nr.: 77,
    eine VL-CDR1-Sequenz gemäß SEQ ID Nr.: 53,
    eine VL-CDR2-Sequenz gemäß SEQ ID Nr.: 54, und
    eine VL-CDR3-Sequenz gemäß SEQ ID Nr.: 55;
    (xi) eine VH-CDR1-Sequenz gemäß SEQ ID Nr.: 57,
    eine VH-CDR2-Sequenz gemäß SEQ ID Nr.: 51,
    eine VH-CDR3-Sequenz gemäß SEQ ID Nr.: 52
    eine VL-CDR1-Sequenz gemäß SEQ ID Nr.: 53,
    eine VL-CDR2-Sequenz gemäß SEQ ID Nr.: 54, und
    eine VL-CDR3-Sequenz gemäß SEQ ID Nr.: 55;
    (xii) eine VH-CDR1-Sequenz gemäß SEQ ID Nr.: 60,
    eine VH-CDR2-Sequenz gemäß SEQ ID Nr.: 51,
    eine VH-CDR3-Sequenz gemäß SEQ ID Nr.: 52,
    eine VL-CDR1-Sequenz gemäß SEQ ID Nr.: 53,
    eine VL-CDR2-Sequenz gemäß SEQ ID Nr.: 54, und
    eine VL-CDR3-Sequenz gemäß SEQ ID Nr.: 55;
    (xiii) eine VH-CDR1-Sequenz gemäß SEQ ID Nr.: 61,
    eine VH-CDR2-Sequenz gemäß SEQ ID Nr.: 51,
    eine VH-CDR3-Sequenz gemäß SEQ ID Nr.: 52,
    eine VL-CDR1-Sequenz gemäß SEQ ID Nr.: 53,
    eine VL-CDR2-Sequenz gemäß SEQ ID Nr.: 54, und
    eine VL-CDR3-Sequenz gemäß SEQ ID Nr.: 55;
    (xiv) eine VH-CDR1-Sequenz gemäß SEQ ID Nr.: 62,
    eine VH-CDR2-Sequenz gemäß SEQ ID Nr.: 51,
    eine VH-CDR3-Sequenz gemäß SEQ ID Nr.: 52,
    eine VL-CDR1-Sequenz gemäß SEQ ID Nr.: 53,
    eine VL-CDR2-Sequenz gemäß SEQ ID Nr.: 54, und
    eine VL-CDR3-Sequenz gemäß SEQ ID Nr.: 55.
  7. Antikörper oder immunologisch aktives Fragment davon nach einem der Ansprüche 1 bis 6, wobei der Antikörper oder das immunologisch aktive Fragment davon umfasst:
    (i) eine VH-Sequenz gemäß SEQ ID Nr.: 5, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 31;
    (ii) eine VH-Sequenz gemäß SEQ ID Nr.: 5, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 32;
    (iii) eine VH-Sequenz gemäß SEQ ID Nr.: 7, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 33;
    (iv) eine VH-Sequenz gemäß SEQ ID Nr.: 7, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 34;
    (v) eine VH-Sequenz gemäß SEQ ID Nr.: 7, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 35;
    (vi) eine VH-Sequenz gemäß SEQ ID Nr.: 7, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 36;
    (vii) eine VH-Sequenz gemäß SEQ ID Nr.: 7, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 37;
    (viii) eine VH-Sequenz gemäß SEQ ID Nr.: 7, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 38;
    (ix) eine VH-Sequenz gemäß SEQ ID Nr.: 7, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 39;
    (x) eine VH-Sequenz gemäß SEQ ID Nr.: 7, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 43;
    (xi) eine VH-Sequenz gemäß SEQ ID Nr.: 8, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 39;
    (xii) eine VH-Sequenz gemäß SEQ ID Nr.: 11, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 42;
    (xiii) eine VH-Sequenz gemäß SEQ ID Nr.: 11, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 43;
    (xiv) eine VH-Sequenz gemäß SEQ ID Nr.: 11, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 44;
    (xv) eine VH-Sequenz gemäß SEQ ID Nr.: 11, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 47;
    (xvi) eine VH-Sequenz gemäß SEQ ID Nr.: 15, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 43;
    (xvii) eine VH-Sequenz gemäß SEQ ID Nr.: 15, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 44;
    (xviii) eine VH-Sequenz gemäß SEQ ID Nr.: 16, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 35;
    (xix) eine VH-Sequenz gemäß SEQ ID Nr.: 17, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 35;
    (xx) eine VH-Sequenz gemäß SEQ ID Nr.: 20, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 35;
    (xxi) eine VH-Sequenz gemäß SEQ ID Nr.: 21, und eine VL-Sequenz gemäß SEQ ID Nr.: 35;
    (xxii) eine VH-Sequenz gemäß SEQ ID Nr.: 22, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 35;
    (xxiii) eine VH-Sequenz gemäß SEQ ID Nr.: 27, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 35;
    (xxiv) eine VH-Sequenz gemäß SEQ ID Nr.: 28, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 35;
    (xxv) eine VH-Sequenz gemäß SEQ ID Nr.: 29, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 35; oder
    (xxvi) eine VH-Sequenz gemäß SEQ ID Nr.: 30, und
    eine VL-Sequenz gemäß SEQ ID Nr.: 35.
  8. Pharmazeutische Zusammensetzung, umfassend den Antikörper oder das immunologisch aktive Fragment davon nach einem der Ansprüche 1 bis 7 und einen Träger.
  9. Antikörper oder immunologisch aktives Fragment davon nach einem der Ansprüche 1 bis 7 zur Verwendung in einem Verfahren zum Lindern eines Symptoms eines Krebses oder einer anderen neoplastischen Krankheit bei einem Subjekt.
  10. Antikörper oder immunologisch aktives Fragment davon zur Verwendung nach Anspruch 9, wobei das Subjekt ein Mensch ist.
  11. Antikörper oder immunologisch aktives Fragment davon zur Verwendung nach Anspruch 9 oder 10, wobei das Verfahren ferner das Verabreichen einer Chemotherapie umfasst.
  12. Antikörper oder immunologisch aktives Fragment davon zur Verwendung nach Anspruch 9 oder 10, wobei das Verfahren ferner das Verabreichen einer Strahlentherapie umfasst.
EP13746964.9A 2012-02-06 2013-02-06 Cd47-antikörper und verfahren zur verwendung davon Active EP2812443B1 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MEP-2019-232A ME03512B (de) 2012-02-06 2013-02-06 Cd47-antikörper und verfahren zur verwendung davon
SI201331564T SI2812443T1 (sl) 2012-02-06 2013-02-06 Protitelesa CD47 in postopki za njihovo uporabo
RSP20191071 RS59159B1 (sr) 2012-02-06 2013-02-06 Cd47 antitela i postupci za njihovu upotrebu
EP19173042.3A EP3578569A1 (de) 2012-02-06 2013-02-06 Cd47-antikörper und verfahren zur verwendung davon
PL13746964T PL2812443T3 (pl) 2012-02-06 2013-02-06 Przeciwciała CD47 i sposoby ich zastosowania
HRP20191500 HRP20191500T1 (hr) 2012-02-06 2019-08-20 Protutijela protiv cd47 i postupci njihove upotrebe

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261595216P 2012-02-06 2012-02-06
US201261659752P 2012-06-14 2012-06-14
PCT/US2013/024995 WO2013119714A1 (en) 2012-02-06 2013-02-06 Cd47 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP19173042.3A Division EP3578569A1 (de) 2012-02-06 2013-02-06 Cd47-antikörper und verfahren zur verwendung davon

Publications (3)

Publication Number Publication Date
EP2812443A1 EP2812443A1 (de) 2014-12-17
EP2812443A4 EP2812443A4 (de) 2015-11-04
EP2812443B1 true EP2812443B1 (de) 2019-05-29

Family

ID=48947976

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13746964.9A Active EP2812443B1 (de) 2012-02-06 2013-02-06 Cd47-antikörper und verfahren zur verwendung davon
EP19173042.3A Pending EP3578569A1 (de) 2012-02-06 2013-02-06 Cd47-antikörper und verfahren zur verwendung davon

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP19173042.3A Pending EP3578569A1 (de) 2012-02-06 2013-02-06 Cd47-antikörper und verfahren zur verwendung davon

Country Status (35)

Country Link
US (4) US9045541B2 (de)
EP (2) EP2812443B1 (de)
JP (1) JP6273212B2 (de)
KR (2) KR102338833B1 (de)
CN (2) CN111533804A (de)
AU (1) AU2013217114B2 (de)
BR (1) BR112014019331A2 (de)
CA (1) CA2863834A1 (de)
CL (1) CL2014002086A1 (de)
CO (1) CO7111273A2 (de)
CR (1) CR20140406A (de)
CY (1) CY1121911T1 (de)
DK (1) DK2812443T3 (de)
EA (1) EA034778B1 (de)
EC (1) ECSP14016994A (de)
ES (1) ES2743203T3 (de)
HK (1) HK1205195A1 (de)
HR (1) HRP20191500T1 (de)
HU (1) HUE13746964T2 (de)
IL (1) IL233934B (de)
LT (1) LT2812443T (de)
ME (1) ME03512B (de)
MX (1) MX360772B (de)
MY (1) MY169341A (de)
NZ (1) NZ628314A (de)
PE (1) PE20141908A1 (de)
PH (1) PH12014501758B1 (de)
PL (1) PL2812443T3 (de)
PT (1) PT2812443T (de)
RS (1) RS59159B1 (de)
SG (2) SG11201404638SA (de)
SI (1) SI2812443T1 (de)
UA (1) UA116772C2 (de)
WO (1) WO2013119714A1 (de)
ZA (1) ZA201405864B (de)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2429574B1 (de) 2009-05-15 2015-05-06 University Health Network Auf sirp-cd47-interaktion gerichtete zusammensetzungen und verfahren zur behandlung von blutkrebs
EP3252076B1 (de) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostische verwendung von antikörpern gegen das protein ror-1
EP2812443B1 (de) 2012-02-06 2019-05-29 Inhibrx, Inc. Cd47-antikörper und verfahren zur verwendung davon
US20140140989A1 (en) * 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
WO2014087248A2 (en) 2012-12-03 2014-06-12 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
WO2014093678A2 (en) 2012-12-12 2014-06-19 Frazier William A Therapeutic cd47 antibodies
AU2013362789B8 (en) 2012-12-17 2018-08-02 Pfizer Inc. Treatment of CD47+ disease cells with SIRP Alpha-Fc fusions
ES2944477T3 (es) * 2013-02-06 2023-06-21 Inhibrx Inc Anticuerpos CD47 no reductores de plaquetas y no reductores de glóbulos rojos y métodos de uso de los mismos
CN112245586A (zh) * 2013-03-15 2021-01-22 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
EP4410833A3 (de) * 2013-12-17 2024-10-23 MHS Care - Innovation LLC Zusammensetzungen und verfahren zur behandlung von fettgewebeaufbau
US11066467B2 (en) 2013-12-17 2021-07-20 Mhs Care-Innovation Llc Compositions and methods for treating ischemic heart disease
CN106456748A (zh) * 2014-01-08 2017-02-22 小利兰·斯坦福大学托管委员会 小细胞肺癌的靶向疗法
AU2015350190B2 (en) 2014-11-18 2021-08-05 Janssen Pharmaceutica Nv CD47 antibodies, methods, and uses
EA037654B1 (ru) * 2014-12-30 2021-04-27 Селджин Корпорейшн Анти-cd47-антитела и их применения
PT3656443T (pt) 2015-01-21 2021-12-27 Univ Leland Stanford Junior Utilização de agonista trl e agente anti-cd47 para melhorar a fagocitose das células cancerígenas
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US10035855B2 (en) * 2015-03-04 2018-07-31 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD47
CN104804093A (zh) * 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
BR112018005322A2 (pt) * 2015-09-18 2018-12-11 Arch Oncology, Inc. anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
CA2999277A1 (en) 2015-09-21 2017-03-30 Surface Oncology, Inc. Anti-cd47 antibodies and methods of use
US10927173B2 (en) 2016-01-11 2021-02-23 Forty Seven, Inc. Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
SI3442578T1 (sl) 2016-04-15 2022-05-31 The Board Of Trustees Of The Leland Standford Junior University Postopki za določanje in doseganje terapevtsko učinkovitih odmerkov sredstev proti CD47 pri zdravljenju raka
JP2019518742A (ja) * 2016-05-09 2019-07-04 セルジーン コーポレーションＣｅｌｇｅｎｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｃｄ４７抗体およびその使用方法
CN106084052B (zh) * 2016-06-17 2019-12-27 长春金赛药业股份有限公司 抗cd47单克隆抗体及其应用
CN106117354B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗CD47的全分子IgG抗体及其应用
BR112019000166A2 (pt) * 2016-07-06 2019-10-01 Celgene Corp anticorpos com baixa imunogenicidade e usos dos mesmos
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
WO2018014068A1 (en) * 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Attenuated type i ifn cd47 combination therapy
CN107955071B (zh) * 2016-10-18 2021-03-26 上海赛远生物科技有限公司 人源抗人cd47抗体及其编码基因与应用
PE20190975A1 (es) * 2016-10-20 2019-07-09 I Mab Novela cd47 anticuerpos monoclonales y sus usos
EP3529276A4 (de) 2016-10-21 2020-06-17 Arch Oncology, Inc. Therapeutische cd47-antikörper
EP3532497B1 (de) 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modifizierte immunoglobulinbandregionen zur verringerung der hämagglutination
US11779631B2 (en) 2016-11-03 2023-10-10 Pfizer Inc. CD47 blockade therapy by HDAC inhibitors
EP3534964A4 (de) 2016-11-03 2020-07-15 Trillium Therapeutics Inc. Verbesserung der cd47-blockadetherapie durch proteasominhibitoren
TW201819413A (zh) * 2016-11-28 2018-06-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｄ４７抗體、其抗原結合片段及其醫藥用途
US11267885B2 (en) * 2017-01-26 2022-03-08 Zlip Holding Limited CD47 antigen binding unit and uses thereof
WO2018175790A1 (en) * 2017-03-22 2018-09-27 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
MX2019012295A (es) 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
WO2018236904A1 (en) 2017-06-19 2018-12-27 Surface Oncology, Inc. COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
CN109096395B (zh) * 2017-06-20 2022-06-24 华兰生物工程股份有限公司 阻断型cd47纳米抗体及其用途
EP3658141B1 (de) 2017-07-24 2022-11-16 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Behandlung pathologischer bedingungen durch direktes und indirektes targeting von sirpa-cd47-interaktion
KR102646468B1 (ko) * 2017-08-02 2024-03-11 페인스 테라퓨틱스 인코포레이티드 항-cd47 항체 및 이의 용도
WO2019034895A1 (en) 2017-08-18 2019-02-21 Ultrahuman Four Limited LIAISON AGENTS
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
JP2021500926A (ja) 2017-11-01 2021-01-14 ハミングバード・バイオサイエンス・ホールディングス・プライベート・リミテッド Ｃｄ４７抗原結合分子
KR102366853B1 (ko) * 2017-11-10 2022-02-23 아이-맵 바이오파마 유에스 리미티드 Cd47 항체 및 사이토카인을 포함하는 융합 단백질
EA202091339A1 (ru) 2017-12-01 2020-10-21 Сиэтл Дженетикс, Инк. Антитела против cd47 и их применение для лечения онкологических заболеваний
KR20200116109A (ko) * 2018-01-24 2020-10-08 난징 레전드 바이오테크 씨오., 엘티디. 상당한 적혈구 응집을 야기하지 않는 항-cd47 항체
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
CN110305212A (zh) 2018-03-27 2019-10-08 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
CN110526972A (zh) * 2018-05-25 2019-12-03 江苏恒瑞医药股份有限公司 一种抗cd47抗体在制备治疗淋巴瘤的药物中的用途
CN110577597B (zh) * 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
EP3806901A4 (de) * 2018-06-15 2022-06-22 Accurus Biosciences, Inc. Blockierende antikörper gegen cd47 und anwendungsverfahren dafür
CN110615841B (zh) * 2018-06-20 2022-01-04 瑞阳(苏州)生物科技有限公司 抗人cd47单克隆抗体及其应用
EP3813884B1 (de) * 2018-06-29 2024-09-18 North Carolina State University In situ gesprühtes bioresponsives immuntherapeutisches gel zur postoperativen behandlung
CN112601544A (zh) * 2018-07-05 2021-04-02 三钰生物科技股份有限公司 人类抗cd47抗体及其用途
CN112601762B (zh) * 2018-08-31 2023-04-04 南京圣和药业股份有限公司 抗cd47抗体及其应用
WO2020088580A1 (en) * 2018-10-31 2020-05-07 I-Mab Biopharma Co., Ltd. Novel cd47 antibodies and methods of using same
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
CN111253488A (zh) * 2018-12-03 2020-06-09 上海开拓者生物医药有限公司 Cd47抗体及其制备方法和应用
TW202104260A (zh) 2019-04-05 2021-02-01 美商西建公司 腫瘤選擇性結合ｃｄ４７之抗體之工程
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
CN110066336B (zh) * 2019-05-12 2021-11-09 杭州科兴生物科技有限公司 抗cd47单克隆抗体、片段及其医药用途
JP7561775B2 (ja) 2019-06-07 2024-10-04 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬
JP7317148B2 (ja) * 2019-06-19 2023-07-28 レプ バイオファーマ カンパニー リミテッド 抗ｃｄ４７抗体およびその使用
CN114761041A (zh) 2019-07-16 2022-07-15 吉利德科学公司 Hiv疫苗及其制备和使用方法
CN110256565B (zh) * 2019-08-02 2021-03-23 天津大学 抗cd47纳米抗体突变体及其应用
CA3149897A1 (en) 2019-09-03 2021-03-11 Daniel Getts Methods and compositions for genomic integration
HUE067160T2 (hu) 2019-09-18 2024-10-28 Lamkap Bio Alpha AG Bispecifikus antitestek CEACAM5 és CD3 ellen
CA3156160A1 (en) * 2019-09-27 2021-04-01 Beijing Starmab Biomed Technology Ltd. Monospecific and multi-specific antibodies
CN118178645A (zh) 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
CN114599681B (zh) * 2019-10-25 2024-01-09 上海药明生物技术有限公司 新型抗cd47抗体及其用途
MX2022005123A (es) 2019-10-31 2022-05-30 Forty Seven Inc Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
DK4081305T3 (da) 2019-12-24 2024-10-14 Carna Biosciences Inc Diacylglycerinkinase modulerende forbindelser
PE20231067A1 (es) 2020-02-14 2023-07-17 Jounce Therapeutics Inc Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos
US11920136B2 (en) 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
EP4112647A4 (de) 2020-02-28 2024-03-27 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-cd47/anti-pd-l1-antikörper und anwendungen davon
JP2023519346A (ja) 2020-03-27 2023-05-10 メンドゥス・ベスローテン・フェンノートシャップ 養子細胞療法の有効性を増強するための白血病由来の改変細胞のエクスビボ（ｅｘ ｖｉｖｏ）使用
US20230303711A1 (en) * 2020-07-31 2023-09-28 Bio-Thera Solutions, Ltd. Anti-cd47 antibody and use thereof
KR20230083300A (ko) 2020-10-07 2023-06-09 셀진 코포레이션 림프계 악성 신생물 병태의 이중특이성 항체 치료
EP4237451A1 (de) 2020-11-02 2023-09-06 Hummingbird Bioscience Pte. Ltd. Bcma/taci-antigen-bindende moleküle
WO2022098905A2 (en) 2020-11-04 2022-05-12 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
EP4256336A1 (de) 2020-12-06 2023-10-11 ALX Oncology Inc. Multimere zur verringerung der störung von arzneimitteln, die cd47 binden, in serologischen tests
KR20220080375A (ko) 2020-12-07 2022-06-14 (주)이노베이션바이오 Cd47에 특이적인 항체 및 이의 용도
EP4262828A1 (de) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Tumorinfiltrierende lymphozyten und anti-cd47-therapeutika
KR20230157388A (ko) 2021-03-12 2023-11-16 멘두스 비.브이. 백신접종의 방법 및 cd47 차단의 용도
AU2022237618A1 (en) 2021-03-17 2023-10-12 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
CA3222595A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
IL309378A (en) 2021-06-23 2024-02-01 Gilead Sciences Inc DIACYLGLYERCOL KINASE MODULATING COMPOUNDS
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP2024527335A (ja) 2021-06-30 2024-07-24 イノベイション バイオ カンパニー リミテッド Ｃｄ４７に特異的なヒト化抗体およびそれを含むｃｄ４７関連疾患の予防または治療用医薬組成物
EP4423078A1 (de) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyrizidin-3(2h)-on-derivate
MX2024005066A (es) 2021-10-29 2024-05-24 Gilead Sciences Inc Compuestos de cd73.
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
EP4245756B1 (de) 2022-03-17 2024-10-09 Gilead Sciences, Inc. Degrader der ikaros-zinkfingerfamilie und verwendungen davon
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024124107A2 (en) 2022-12-09 2024-06-13 Pfizer Inc. Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy
WO2024121777A1 (en) 2022-12-09 2024-06-13 Pfizer Inc. Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy
CN118221812A (zh) * 2022-12-14 2024-06-21 上海迈石生物技术有限公司 一种靶向cd47的单克隆抗体及其应用
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024177978A1 (en) * 2023-02-24 2024-08-29 The Regents Of The University Of California Lilrb3 engager cells
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN117004700A (zh) * 2023-10-07 2023-11-07 北京爱博生生物技术有限公司 单克隆抗体可变区基因高通量测序的方法及其所用组合物与试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1931710A2 (de) 2005-08-31 2008-06-18 Schering Corporation Konstruierte anti-il-23-antikörper

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0279862B1 (de) 1986-08-28 1993-11-03 Teijin Limited Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5057604A (en) 1988-08-03 1991-10-15 Washington University Novel monoclonal antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
JP3070763B2 (ja) 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0746609A4 (de) 1991-12-17 1997-12-17 Genpharm Int Heterologe antikörper produzierende transgene nicht-humane tiere
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
WO1993016043A1 (en) 1992-02-18 1993-08-19 Otsuka Kagaku Kabushiki Kaisha β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
NZ253943A (en) 1992-06-18 1997-01-29 Genpharm Int Transfering polynucleotides into eukaryotic cells using co-lipofection complexes of a cationic lipid and the polynucleotide
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
ATE211762T1 (de) 1993-04-30 2002-01-15 Biognostik Ges Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
EP0703979B1 (de) 1993-06-04 2000-09-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
EP0823941A4 (de) 1995-04-28 2001-09-19 Abgenix Inc Menschliche antikörper aus xenomäusen
DK0843961T3 (da) 1995-08-29 2007-05-21 Kirin Brewery Kimærisk mus og fremgangsmåde til at producere samme
US6025130A (en) 1996-04-04 2000-02-15 Mercator Genetics, Inc. Hereditary hemochromatosis gene
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
EP1035132B1 (de) * 1997-09-11 2008-05-14 Chugai Seiyaku Kabushiki Kaisha Monoklonale antikörper zur apoptosis-induzierung
AU2940900A (en) 1999-03-10 2000-09-28 Chugai Seiyaku Kabushiki Kaisha Single-stranded fv inducing apoptosis
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7282556B2 (en) 2001-05-15 2007-10-16 Emory University Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47
KR100454414B1 (ko) 2001-06-25 2004-10-26 주식회사 진생사이언스 산소를 이용한 개량 홍삼의 제조 방법
AU2003276832A1 (en) 2002-05-10 2004-02-25 Medimmune, Llc EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
WO2003102215A2 (en) 2002-05-31 2003-12-11 The Board Of Trustees Of The Leland Stanford Junior University Methods of identifying and isolating stem cells and cancer stem cells
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20100215640A1 (en) 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
CN101133083A (zh) * 2003-11-11 2008-02-27 中外制药株式会社 人源化的抗cd47抗体
US7816088B2 (en) 2003-12-05 2010-10-19 The Board Of Trustees Of The Leland Stanford Junior University Identification, isolation and elimination of cancer stem cells
PT1707627E (pt) 2003-12-25 2013-01-24 Kyowa Hakko Kirin Co Ltd Mutante antagonista de anticorpo anti-cd40
WO2005079479A2 (en) * 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
WO2005117936A2 (en) 2004-05-07 2005-12-15 The University Of North Carolina At Chapel Hill Method for enhancing or inhibiting insulin-like growth factor-i
US7728880B2 (en) 2004-06-25 2010-06-01 Qualcomm Incorporated Automatic white balance method and apparatus
US20090191202A1 (en) 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
CA2652570A1 (en) * 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
US7879984B2 (en) 2007-07-31 2011-02-01 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
KR101710472B1 (ko) 2007-11-30 2017-02-27 글락소 그룹 리미티드 항원-결합 작제물
CA2711370C (en) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
ES2740823T3 (es) 2008-01-15 2020-02-06 Univ Leland Stanford Junior Métodos para manipular fagocitosis mediada por CD47
KR100962704B1 (ko) 2008-07-02 2010-06-11 유상규 일측 단말의 제어로 타 단말의 주변장치를 이용하는 단말장치 및 그 인터페이스 방법
AU2009281713B9 (en) 2008-08-14 2014-05-29 Teva Pharmaceuticals Australia Pty Ltd Anti-IL-12/IL-23 antibodies
EP3130674B1 (de) * 2008-11-03 2020-07-08 ADC Therapeutics SA Antikörper für die spezifische blockierung der biologischen aktivität eines tumorantigens
CA2771336C (en) 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
US9151760B2 (en) 2009-09-29 2015-10-06 The Board Of Trustees Of The Leland Stanford Junior University Isolation and use of melanoma cancer stem cells
US20120283124A1 (en) 2009-11-10 2012-11-08 Park Christopher Y Cell Surface Marker Expression in Hematopoietic Stem Cells and Progenitors for the Diagnosis, Prognosis, and Treatment of Myelodysplastic Syndromes
LT3789038T (lt) 2010-05-14 2022-12-12 The Board Of Trustees Of The Leland Stanford Junior University Humanizuoti ir chimeriniai monokloniniai antikūnai prieš cd47
US20130281304A1 (en) 2010-08-13 2013-10-24 Andrew P. Feinberg Comprehensive Methylome Map of Myeloid and Lymphoid Commitment from Hematopoietic Proenitors
US20140271683A1 (en) 2010-12-21 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor
PL2804617T3 (pl) 2012-01-17 2020-11-30 The Board Of Trustees Of The Leland Stanford Junior University Reagenty sirp-alfa o wysokim powinowactwie
US20140140989A1 (en) * 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
EP2812443B1 (de) 2012-02-06 2019-05-29 Inhibrx, Inc. Cd47-antikörper und verfahren zur verwendung davon
WO2014036385A1 (en) 2012-08-31 2014-03-06 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (igf-1)
ES2944477T3 (es) 2013-02-06 2023-06-21 Inhibrx Inc Anticuerpos CD47 no reductores de plaquetas y no reductores de glóbulos rojos y métodos de uso de los mismos
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1931710A2 (de) 2005-08-31 2008-06-18 Schering Corporation Konstruierte anti-il-23-antikörper

Also Published As

Publication number Publication date
CR20140406A (es) 2014-12-10
US20150238604A1 (en) 2015-08-27
CN104271757A (zh) 2015-01-07
LT2812443T (lt) 2019-09-10
CL2014002086A1 (es) 2015-02-27
IL233934A0 (en) 2014-09-30
US20130224188A1 (en) 2013-08-29
WO2013119714A1 (en) 2013-08-15
MY169341A (en) 2019-03-21
CY1121911T1 (el) 2020-10-14
CN111533804A (zh) 2020-08-14
PL2812443T3 (pl) 2020-01-31
PT2812443T (pt) 2019-09-05
EP3578569A1 (de) 2019-12-11
US9045541B2 (en) 2015-06-02
US20160251435A1 (en) 2016-09-01
KR102100388B1 (ko) 2020-04-13
KR20200040897A (ko) 2020-04-20
SI2812443T1 (sl) 2019-10-30
PE20141908A1 (es) 2014-12-21
KR20150008049A (ko) 2015-01-21
ECSP14016994A (es) 2015-09-30
DK2812443T3 (da) 2019-08-26
PH12014501758A1 (en) 2014-11-10
MX2014009427A (es) 2015-05-11
PH12014501758B1 (en) 2014-11-10
CO7111273A2 (es) 2014-11-10
ES2743203T3 (es) 2020-02-18
SG11201404638SA (en) 2014-09-26
EA034778B1 (ru) 2020-03-19
SG10201700160RA (en) 2017-03-30
EP2812443A4 (de) 2015-11-04
US20210317205A1 (en) 2021-10-14
JP2015508072A (ja) 2015-03-16
CN104271757B (zh) 2020-06-09
MX360772B (es) 2018-11-15
EA201400875A1 (ru) 2015-01-30
HUE13746964T2 (hu) 2020-01-28
UA116772C2 (uk) 2018-05-10
HRP20191500T1 (hr) 2019-11-29
NZ628314A (en) 2017-01-27
AU2013217114A1 (en) 2014-09-18
AU2013217114B2 (en) 2017-03-30
EP2812443A1 (de) 2014-12-17
US9663575B2 (en) 2017-05-30
KR102338833B1 (ko) 2021-12-13
IL233934B (en) 2022-04-01
BR112014019331A2 (pt) 2022-07-12
ME03512B (de) 2020-04-20
JP6273212B2 (ja) 2018-01-31
BR112014019331A8 (pt) 2018-01-16
HK1205195A1 (en) 2015-12-11
RS59159B1 (sr) 2019-10-31
ZA201405864B (en) 2015-11-25
CA2863834A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
US20210317205A1 (en) Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
US20210371522A1 (en) Cd47 antibodies and methods of use thereof
US20240166744A1 (en) Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
AU2019200942B2 (en) Non-platelet depleting and non-red blood cell depleting CD47 antibodies and methods of use thereof
WO2019144895A1 (en) Anti-cd47 antibodies that do not cause significant red blood cell agglutination

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140904

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151006

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20150930BHEP

Ipc: C12P 21/08 20060101AFI20150930BHEP

Ipc: A61K 39/395 20060101ALI20150930BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1205195

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INHIBRX LP

17Q First examination report despatched

Effective date: 20160729

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INHIBRX, INC.

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20181207

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RAZAI, AMIR

Inventor name: NGUY, PETER, L.

Inventor name: DEVERAUX, QUINN

Inventor name: TIMMER, JOHN

Inventor name: ECKELMAN, BRENDAN

Inventor name: JONES, KYLE

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013056024

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1138275

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190615

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: VALIPAT S.A. C/O BOVARD SA NEUCHATEL, CH

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20191500T

Country of ref document: HR

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190819

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2812443

Country of ref document: PT

Date of ref document: 20190905

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20190819

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E017981

Country of ref document: EE

Effective date: 20190819

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20190529

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 31827

Country of ref document: SK

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20191500

Country of ref document: HR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20190402531

Country of ref document: GR

Effective date: 20191128

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20191500

Country of ref document: HR

Payment date: 20200121

Year of fee payment: 8

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2743203

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200218

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602013056024

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: FORTY SEVEN, INC.

Effective date: 20200228

REG Reference to a national code

Ref country code: FI

Ref legal event code: MDE

Opponent name: FORTY SEVEN, INC.

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20191500

Country of ref document: HR

Payment date: 20210111

Year of fee payment: 9

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: FORTY SEVEN, INC.

Effective date: 20200228

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1138275

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190529

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20191500

Country of ref document: HR

Payment date: 20220204

Year of fee payment: 10

R26 Opposition filed (corrected)

Opponent name: FORTY SEVEN, INC.

Effective date: 20200228

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20191500

Country of ref document: HR

Payment date: 20230118

Year of fee payment: 11

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230514

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20231229

Year of fee payment: 12

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20191500

Country of ref document: HR

Payment date: 20240122

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240108

Year of fee payment: 12

Ref country code: MK

Payment date: 20230110

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240129

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240110

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20240109

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20240103

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240305

Year of fee payment: 12

Ref country code: IE

Payment date: 20240103

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240125

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20240126

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20240130

Year of fee payment: 12

Ref country code: RO

Payment date: 20240126

Year of fee payment: 12

Ref country code: HU

Payment date: 20240116

Year of fee payment: 12

Ref country code: FI

Payment date: 20240213

Year of fee payment: 12

Ref country code: EE

Payment date: 20240103

Year of fee payment: 12

Ref country code: DE

Payment date: 20231229

Year of fee payment: 12

Ref country code: CZ

Payment date: 20240118

Year of fee payment: 12

Ref country code: CY

Payment date: 20240109

Year of fee payment: 12

Ref country code: BG

Payment date: 20240125

Year of fee payment: 12

Ref country code: PT

Payment date: 20240206

Year of fee payment: 12

Ref country code: CH

Payment date: 20240301

Year of fee payment: 12

Ref country code: SK

Payment date: 20240115

Year of fee payment: 12

Ref country code: GB

Payment date: 20240108

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20240116

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240205

Year of fee payment: 12

Ref country code: SE

Payment date: 20240103

Year of fee payment: 12

Ref country code: RS

Payment date: 20240112

Year of fee payment: 12

Ref country code: PL

Payment date: 20240117

Year of fee payment: 12

Ref country code: NO

Payment date: 20240208

Year of fee payment: 12

Ref country code: MT

Payment date: 20240219

Year of fee payment: 12

Ref country code: LV

Payment date: 20240103

Year of fee payment: 12

Ref country code: IT

Payment date: 20240111

Year of fee payment: 12

Ref country code: HR

Payment date: 20240122

Year of fee payment: 12

Ref country code: DK

Payment date: 20240214

Year of fee payment: 12

Ref country code: BE

Payment date: 20240105

Year of fee payment: 12

REG Reference to a national code

Ref country code: HR

Ref legal event code: PPPP

Ref document number: P20191500

Country of ref document: HR

Owner name: INHIBRX BIOSCIENCES, INC., US

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602013056024

Country of ref document: DE

Owner name: INHIBRX BIOSCIENCES, INC. (N.D.GES.D.STAATES D, US

Free format text: FORMER OWNER: INHIBRX, INC., LA JOLLA, CA, US

REG Reference to a national code

Ref country code: EE

Ref legal event code: GB1A

Ref document number: E017981

Country of ref document: EE

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: INHIBRX BIOSCIENCES, INC.; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: INHIBRX, INC.

Effective date: 20240724

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

REG Reference to a national code

Ref country code: LU

Ref legal event code: PD

Owner name: INHIBRX BIOSCIENCES, INC.; US

Free format text: FORMER OWNER: INHIBRX, INC.

Effective date: 20240705

REG Reference to a national code

Ref country code: SK

Ref legal event code: PC4A

Ref document number: E 31827

Country of ref document: SK

Owner name: INHIBRX BIOSCIENCES, INC., LA JOLLA, CA, US

Free format text: FORMER OWNER: INHIBRX, INC., LA JOLLA, CA, US

Effective date: 20240716

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: INHIBRX BIOSCIENCES, INC.; US

Effective date: 20240716

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20240207

Year of fee payment: 12

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: INHIBRX BIOSCIENCES, INC.

Effective date: 20241028